Form 8-K

8-K — Banzai International, Inc.

Accession: 0001493152-26-042422

Filed: 2026-09-11

Period: 2026-09-11

CIK: 0001826011

SIC: 7372 (SERVICES-PREPACKAGED SOFTWARE)

Item: Entry into a Material Definitive Agreement

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-4.1 (ex4-1.htm)

EX-4.2 (ex4-2.htm)

EX-10.1 (ex10-1.htm)

EX-10.2 (ex10-2.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001826011

2026-09-11

0001826011

BNZI:ClassCommonStockParValue0.0001PerShareMember

2026-09-11

0001826011

BNZI:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceOf115000.00Member

2026-09-11

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

PURSUANT

TO SECTION 13 OR 15(D)

THE SECURITIES EXCHANGE ACT OF 1934

Date

of Report (Date of earliest event reported): September 11, 2026

Banzai

International, Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-39826

85-3118980

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(I.R.S.

Employer

Identification

No.)

435

Ericksen Ave, Suite 250

Bainbridge

Island, Washington

98110

(Address

of Principal Executive Offices)

(Zip

Code)

Registrant’s

telephone number, including area code: (206) 414-1777

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Class

A common stock, par value $0.0001 per share

PARA

The

Nasdaq Capital Market

Redeemable

Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $115,000.00

PARAW

The

Nasdaq Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

1.01. Entry into a Material Definitive Agreement.

September 4, 2026, Banzai International, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase

Agreement”) with an accredited investor (the “Purchaser”). Pursuant to the Purchase Agreement, the Company

agreed to issue and sell to the Purchaser, in a private placement (the “Private Placement”), (i) a convertible promissory

note (the “Note”) in an initial principal amount of $2,142,857, subject to increase up to $3,571,428 in aggregate

principal amount, and (ii) a warrant (the “Common Warrant”) to purchase up to 779,221 shares of the Company’s

Class A common stock, par value $0.0001 per share (the “Common Stock”), with additional Common Warrants to purchase

up to 519,480 additional shares of Common Stock issuable in connection with subsequent tranche fundings. The Private Placement was made

in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities

Act”), and Rule 506 promulgated thereunder. Aegis Capital Corp. (the “Placement Agent”) acted as the exclusive

placement agent for the Private Placement.

The

Purchaser’s subscription amount is payable in up to three tranches; $1,500,000 of which was paid upon execution and delivery of

the Purchase Agreement (the “Initial Closing”) and the remaining $1,000,000 of which shall be due in two equal tranches

upon the occurrence of certain specified events.

Upon

the funding of the remaining two tranches, the outstanding principal amount of the Note will automatically be increased by $714,285

and $714,285, respectively, and the Company will issue to the Purchaser, in connection with each such tranche funding, an additional

Common Warrant to purchase up to 259,740 shares of Common Stock. The gross proceeds to the Company from the Initial Closing were $1,500,000,

before deducting placement agent fees of 10%, investor legal fees, and other offering expenses.

The

Company is also required to hold a special meeting of stockholders (or present the matter at an annual meeting) no later than sixty (60)

calendar days after the closing date to seek stockholder approval to, among other things, issue in excess of twenty percent (20%) of

the outstanding shares of Common Stock at a deemed discount to the Nasdaq Minimum Price (as defined in Nasdaq Listing Rule 5635(d)(1)(A))

immediately prior to execution of the Purchase Agreement, and the voluntary adjustment of the exercise price of the Common Warrant.

Convertible

Promissory Notes

The

Note was issued with an initial principal amount of $2,142,857, an original issue discount of thirty percent (30%), and bears interest

at a rate of ten percent (10%) per annum, maturing on June 4, 2027 (nine months from the issuance date). Upon an event of default, interest

will accrue at a default rate of eighteen percent (18%) per annum.

The

Note is convertible, at the option of the holder, into shares of Common Stock at a fixed conversion price of $2.75 per share (subject

to adjustment for stock splits, stock dividends, combinations, recapitalizations, and similar events), subject to a beneficial ownership

limitation of 4.99% (subject to increase to 9.99% upon sixty-one (61) calendar days’ prior notice by the holder) and an exchange

cap of 19.99% of the shares of Common Stock outstanding immediately prior to execution of the Purchase Agreement, unless and until stockholder

approval is obtained.

Upon

an event of default (which includes, among other things, failure to make payments when due, material breaches of representations or covenants,

bankruptcy events, delisting of the Common Stock from the Nasdaq Capital Market for more than five (5) consecutive trading days, and

the occurrence of a material adverse effect that materially impairs the Company’s ability to perform its obligations under the

Note), the outstanding principal of the Note will automatically be increased by twenty percent (20%), and the holder may declare the

entire principal amount, together with all accrued and unpaid interest, immediately due and payable.

The

Company may voluntarily prepay all or any portion of the Note at 110% of the outstanding amount upon five (5) trading days’ prior

written notice. In addition, upon any subsequent financing (other than a qualified public offering resulting in aggregate gross proceeds

of not less than $5,000,000), the Company must apply fifty percent (50%) of the net cash proceeds to prepayment of the Note, and upon

consummation of a qualified public offering, the entire outstanding amount of the Note will become immediately due and payable in full.

Without

the holder’s prior consent, the Note restricts the Company from, among other things, issuing variable-rate securities, declaring

or paying dividends on Common Stock, redeeming or repurchasing shares of Common Stock, and transferring assets outside the ordinary course

of business.

Common

Warrant

The

Common Warrant entitles the holder to purchase up to 779,221 shares of Common Stock (subject to increase in connection with Tranche 2

and Tranche 3 fundings) at an exercise price of $2.75 per share, subject to adjustment, and is immediately exercisable upon issuance,

expiring on the fifth anniversary of the issuance date (the “Expiration Date”). The Common Warrant may be

exercised on a cashless basis at any time when there is no effective registration statement covering the resale of the underlying shares,

and any unexercised portion will be automatically exercised via cashless exercise on the termination date. Exercise is subject to a beneficial

ownership limitation of 4.99% (subject to increase to 9.99% upon sixty-one (61) calendar days’ prior notice by the holder) and

the same exchange cap applicable to the Note.

the Company fails to pay all outstanding principal, accrued and unpaid interest, and any other amounts then due under the

Note in full within ninety (90) calendar days of the Initial Closing, then at any time between the Initial Closing and

the Expiration Date, the exercise price of the Common Warrant will be subject to anti-dilution adjustment in the event of any subsequent

dilutive issuance, reducing the exercise price to the lower of the dilutive issuance price or the lowest volume weighted average price

of the Common Stock during the five (5) consecutive trading days immediately following such dilutive issuance.

the event of a Fundamental Transaction (as defined in the Common Warrant), the holder will have the right to receive, upon

exercise, the same consideration that holders of Common Stock received in such transaction, or, at the holder’s option, to require

the Company or the successor entity to purchase the unexercised portion of the Common Warrant for cash at the Black Scholes Value (as

defined in the Common Warrant).

Lock-Up

Agreements

connection with the Private Placement, each of the Company’s directors, executive officers, and stockholders holding at least ten

percent (10%) of the outstanding shares of Common Stock entered into lock-up agreements (the “Lock-Up Agreements”)

with the Company, pursuant to which, subject to certain limited exceptions, such persons are restricted from offering, selling,

entering into a contract to sell, loaning, pledging, granting a security interest in, or otherwise disposing of the shares they hold,

for a period of 90 calendar days from the date of the Purchase Agreement (the “Lock-Up Period”).

The

foregoing descriptions of the Purchase Agreement, the Note, the Common Warrant, and the Lock-Up Agreements are qualified in their entirety

by reference to the full text of such documents, which are filed as exhibits to this Current Report on Form 8-K and incorporated herein

by reference.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

No.

Description

4.1

Convertible Promissory Note, dated September 4, 2026, issued by Banzai International, Inc. to Evergreen Capital Management LLC.

4.2

Common Stock Purchase Warrant, dated September 4, 2026, issued by Banzai International, Inc. to Evergreen Capital Management LLC.

10.1

Securities Purchase Agreement, dated September 4, 2026, by and between Banzai International, Inc. and Evergreen Capital Management LLC.

10.2

Form of Lock-Up Agreement.

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Dated:

September 11, 2026

BANZAI

INTERNATIONAL, INC.

By:

/s/

Joseph Davy

Joseph

Davy

Chief

Executive Officer

EX-4.1

Filename: ex4-1.htm · Sequence: 2

Exhibit

4.1

CONVERTIBLE

PROMISSORY NOTE

NEITHER

THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE

HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED

FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES

ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO

THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE

144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER

LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES. ANY TRANSFEREE OF THIS CONVERTIBLE PROMISSORY NOTE SHOULD CAREFULLY REVIEW THE

TERMS OF THIS CONVERTIBLE PROMISSORY NOTE. THE PRINCIPAL AMOUNT REPRESENTED BY THIS CONVERTIBLE PROMISSORY NOTE AND, ACCORDINGLY, THE

SECURITIES ISSUABLE UPON CONVERSION HEREOF MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO THE TERMS OF THIS CONVERTIBLE

PROMISSORY NOTE.

THIS

NOTE HAS BEEN ISSUED WITH ORIGINAL ISSUE DISCOUNT (“OID”). PURSUANT TO TREASURY REGULATION §1.1275-3(b)(1), DEAN DITTO,

A REPRESENTATIVE OF THE COMPANY HEREOF WILL, BEGINNING TEN DAYS AFTER THE ISSUANCE DATE OF THIS NOTE, PROMPTLY MAKE AVAILABLE TO THE

HOLDER UPON REQUEST THE INFORMATION DESCRIBED IN TREASURY REGULATION §1.1275-3(b)(1)(i). DEAN DITTO MAY BE REACHED AT TELEPHONE

NUMBER 206-414-1777.

BANZAI

INTERNATIONAL, INC.

CONVERTIBLE

PROMISSORY NOTE DUE JUNE 4, 2027

Issuance Date: September 4, 2026

Principal Amount:

$2,142,857.14

FOR

VALUE RECEIVED, BANZAI INTERNATIONAL, INC., a Delaware corporation (the “Company”), hereby promises to pay to

the order of Evergreen Capital Management LLC or its registered assigns (“Holder”) the amount set forth above as the

original principal amount (the “Principal”) when due on the date that is nine (9) months after the Issuance Date (the

“Maturity Date”), or upon acceleration, prepayment or otherwise (in each case in accordance with the terms hereof)

and to pay interest (“Interest”) on any outstanding Principal at the Interest Rate and, if applicable, at the Default

Interest rate (in each case as defined below), as set forth herein until the same becomes due and payable, whether upon the Maturity

Date or upon acceleration, conversion, prepayment or otherwise (in each case in accordance with the terms hereof). This Convertible Promissory

Note (this “Note”) is issued to the Holder as of the date set forth above as the Issuance Date (the “Issuance

Date”) by the Company. Certain capitalized terms used herein are defined in Section 23; any capitalized terms used but not

defined herein shall have the meaning assigned to such terms in the Securities Purchase Agreement (defined below).

PAYMENTS OF PRINCIPAL.

(a)

On the Maturity Date, the Company shall pay to the Holder an amount in cash representing all outstanding Principal and accrued and unpaid

Interest on such Principal, together with all other amounts then due and owing under this Note.

(b)

Increase Upon Funding of Tranche 2. Upon the funding of Tranche 2 (as defined in the Securities Purchase Agreement) in accordance

with the Securities Purchase Agreement, the outstanding Principal of this Note shall automatically, and without any further action on

the part of the Company or the Holder, be increased by $714,285.71, and the Company shall, at its sole cost, execute and deliver to the

Holder an amended and restated Note reflecting such increase; provided that the failure to deliver any such amended and restated Note

shall not affect such automatic increase.

(c)

Increase Upon Funding of Tranche 3. Upon the funding of Tranche 3 (as defined in the Securities Purchase Agreement) in accordance

with the Securities Purchase Agreement, the outstanding Principal of this Note shall automatically, and without any further action on

the part of the Company or the Holder, be increased by $714,285.72, and the Company shall, at its sole cost, execute and deliver to the

Holder an amended and restated Note reflecting such increase; provided that the failure to deliver any such amended and restated Note

shall not affect such automatic increase.

INTEREST RATE; DEFAULT RATE.

(a)

Interest shall accrue on the Principal from the Issuance Date at a rate of ten percent (10%) per annum (the “Interest Rate”).

Interest at the Interest Rate is not subject to rebate, proration or reduction upon any prepayment, conversion or acceleration. This

Note was issued with an original issue discount of thirty percent (30%) of the Principal.

(b)

From and after the occurrence and during the continuance of any Event of Default, the Note shall accrue interest, in lieu of interest

at the Interest Rate, at a rate per annum equal to eighteen percent (18%) (the “Default Interest”), provided,

however, that in no event shall the Default Interest exceed the maximum rate permitted by applicable law. Default Interest shall

be due and payable on the first Trading Day of each calendar month during the continuance of such Event of Default (a “Default

Interest Payment Date”). In the event that such Event of Default is subsequently cured and no other Event of Default then exists

(including, without limitation, for the Company’s failure to pay such Default Interest on the applicable Default Interest Payment

Date), then the Note shall cease accruing Default Interest effective as of the day immediately following the date of such cure; provided

that the Default Interest as calculated and unpaid at such increased rate during the continuance of such Event of Default shall continue

to apply to the extent relating to the days after the occurrence of such Event of Default through and including the date of such cure

of such Event of Default.

CONVERSION OF NOTE. This Note shall be convertible into validly issued, fully paid and non-assessable Common Stock (the “Conversion

Shares”) on the terms and conditions set forth in this Section 3.

(a)

Conversion Right. At any time after the initial Closing, the Holder shall be entitled to convert any portion of the outstanding

and unpaid Conversion Amount (as defined below) into Conversion Shares in accordance with Section 3(b), at the Conversion Rate (as defined

below). The Company shall not issue any fraction of a Conversion Share upon any conversion. If the issuance would result in the issuance

of a fraction of a share of Common Stock, the Company shall round such fraction of a share of Common Stock up to the nearest whole share;

provided that no shares of Common Stock shall be issued at a discount to its par value. The Company shall pay any and all transfer, stamp,

issuance and similar taxes, costs and expenses (including, without limitation, fees and expenses of the Transfer Agent (as defined below))

that may be payable with respect to the issuance and delivery of Common Stock upon conversion of any Conversion Amount. If the Company

fails or refuses to deliver any legal opinion required to be delivered by it (or to cause its counsel to deliver any such opinion) under

this Note or the other Transaction Documents, or required to permit the removal of any restrictive legend or the issuance of Conversion

Shares without a restrictive legend, and the Holder obtains such legal opinion at its own expense, the Company shall promptly reimburse

the Holder for all reasonable costs and expenses (including reasonable attorneys’ fees) incurred by the Holder in connection therewith,

and, at the Holder’s election, any such amount not so reimbursed shall be added to, and shall thereafter constitute, outstanding

Principal under this Note for all purposes (including, without limitation, the accrual of Default Interest under Section 2 and the application

of the Default Principal Increase under Section 4(c)).

(b)

Conversion Rate. The number of Conversion Shares issuable upon conversion of any Conversion Amount pursuant to Section 3(a) shall

be determined by dividing (x) such Conversion Amount by (y) the Conversion Price (the “Conversion Rate”).

(i)

“Conversion Amount” means the sum of (x) the portion of the Principal to be converted, prepaid or otherwise with respect

to which this determination is being made and (y) all accrued and unpaid Interest with respect to such portion of the Principal amount

and (z) all other amounts then due and owing under this Note with respect to such portion of the Principal (including, without limitation,

any Default Principal Increase, any liquidated damages, and any costs, fees and expenses reimbursable to the Holder, in each case to

the extent allocable to such portion of the Principal).

(ii)

“Conversion Price” means $2.75 per share (the “Fixed Conversion Price”), subject to adjustment as set

forth in this Note. The Conversion Price shall not at any time fall below the par value of the Common Stock.

(c)

Mechanics of Conversion.

(i)

Optional Conversion. To convert any Conversion Amount into Conversion Shares on any date (a “Conversion Date”),

the Holder shall deliver to the Company (whether via facsimile, electronic mail or otherwise), for receipt on or prior to 11:59 p.m.,

New York time, on such date, a copy of an executed notice of conversion in the form attached hereto as Exhibit I (the “Conversion

Notice”). If required pursuant to Section 3(c)(iii) hereof, within two Trading Days following a conversion of this Note as

aforesaid, the Holder shall surrender this Note to a nationally recognized overnight delivery service for delivery to the Company (or

an indemnification undertaking with respect to this Note in the case of its loss, theft or destruction as contemplated by Section 12(b)).

On (i) the same Trading Day on which the Company has received a Conversion Notice, in the case of a Conversion Notice received by the

Company at or prior to 12:00 p.m., New York time, on a Trading Day, and (ii) 11:00 a.m., New York time, on the Trading Day immediately

following the date on which the Company has received a Conversion Notice, in the case of a Conversion Notice received by the Company

after 12:00 p.m., New York time, or on a day that is not a Trading Day (or such earlier date as required pursuant to the Securities Exchange

Act of 1934, as amended (the “Exchange Act”) or other applicable law, rule or regulation for the settlement of a trade

initiated on the applicable Conversion Date of such Common Stock issuable pursuant to such Conversion Notice), the Company shall (1)

provided that its transfer agent is participating in the DTC Fast Automated Securities Transfer Program, credit such aggregate number

of shares of Common Stock to which the Holder shall be entitled pursuant to such conversion to the Holder’s or its designee’s

balance account with DTC through its Deposit/Withdrawal at Custodian system or (2) if its transfer agent is not participating in the

DTC Fast Automated Securities Transfer Program, upon the request of the Holder, issue and deliver (via reputable overnight courier) to

the address as specified in the Conversion Notice, a certificate, registered in the name of the Holder or its designee, for the number

of shares of Common Stock to which the Holder shall be entitled pursuant to such conversion. If this Note is physically surrendered for

conversion pursuant to Section 3(c)(iii) and the outstanding Principal of this Note is greater than the Principal portion of the Conversion

Amount being converted, then the Company shall as soon as practicable and in no event later than two (2) Trading Days after receipt of

this Note and at its own expense, issue and deliver to the Holder (or its designee) a new Note (in accordance with Section 12(d)) representing

the outstanding Principal not converted. The Person or Persons entitled to receive the Conversion Shares shall be treated for all purposes

as the record holder or holders of such Common Stock on the Conversion Date. If the Company fails, for any reason or for no reason, to

deliver to the Holder the Conversion Shares to which the Holder is entitled by the applicable delivery deadline set forth in this Section

3(c)(i) (a “Delivery Failure”), then, in addition to all other remedies available to the Holder, the Company shall

pay to the Holder, in cash, the product of (x) the number of such Conversion Shares and (y) the difference between the highest trade

price and the lowest trade price of the Common Stock on the Principal Market during the period beginning on the applicable Conversion

Date and ending on the date on which such Conversion Shares are delivered to the Holder’s prime broker and are available to be

sold by the Holder. The Company agrees to maintain, at all times while this Note remains outstanding, a transfer agent that is a participant

in the DTC Fast Automated Securities Transfer Program. In addition, if, on or after the applicable delivery deadline, the Holder is required

by its broker to purchase (in an open market transaction or otherwise), or the Holder’s brokerage firm otherwise purchases, Common

Stock to deliver in satisfaction of a sale by the Holder of Conversion Shares that the Holder anticipated receiving from the Company

(a “Buy-In”), then the Company shall, at the Holder’s election, (A) pay in cash to the Holder the amount, if

any, by which the Holder’s total purchase price (including brokerage commissions, if any) for the Common Stock so purchased exceeds

the product of (x) the aggregate number of Conversion Shares that the Company was required to deliver multiplied by (y) the price at

which the sell order giving rise to such Buy-In was executed, and (B) either reinstate the portion of this Note and equivalent number

of Conversion Shares for which such conversion was not honored (in which case such conversion shall be deemed rescinded) or deliver to

the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its delivery obligations

hereunder. Nothing herein shall prohibit the Holder from seeking to enforce damages pursuant to any other Section hereof or under applicable

law.

(ii)

Reserved.

(iii)

Registration; Book-Entry. The Company shall maintain a register (the “Register”) for the recordation of the

names and addresses of the Holder of the Note and the principal amount of the Note (the “Registered Note”). The entries

in the Register shall be conclusive and binding for all purposes absent manifest error. The Company and the holder or holders of the

Note shall treat each Person whose name is recorded in the Register as the owner of a Note for all purposes (including, without limitation,

the right to receive payments of Principal and Interest hereunder) notwithstanding notice to the contrary. The Registered Note may, subject

to Section 22 hereof, be assigned, transferred or sold in whole or in part only by registration of such assignment or sale on the Register.

Upon its receipt of a written request to assign, transfer or sell all or part of the Registered Note by the holder thereof, the Company

shall record the information contained therein in the Register and issue one or more new Registered Notes in the same aggregate principal

amount as the principal amount of the surrendered Registered Note to the designated assignee or transferee pursuant to Section 12, provided

that if the Company does not so record an assignment, transfer or sale (as the case may be) of all or part of any Registered Note within

two (2) Trading Days of such a request, then the Register shall be automatically deemed updated to reflect such assignment, transfer

or sale (as the case may be). Notwithstanding anything to the contrary set forth in this Section 3, following conversion of any portion

of this Note in accordance with the terms hereof, the Holder shall not be required to physically surrender this Note to the Company unless

(A) the full Conversion Amount represented by this Note is being converted (in which event this Note shall be delivered to the Company

following conversion thereof) or (B) the Holder has provided the Company with prior written notice (which notice may be included in a

Conversion Notice) requesting reissuance of this Note upon physical surrender of this Note. The Holder and the Company shall maintain

records showing the Principal and Interest converted and/or paid (as the case may be) and the dates of such conversions, and/or payments

(as the case may be) or shall use such other method, reasonably satisfactory to the Holder and the Company, so as not to require physical

surrender of this Note upon conversion. If the Company does not update the Register to record such Principal and Interest converted and/or

paid (as the case may be) and the dates of such conversions, and/or payments (as the case may be) within three (3) Trading Days of such

occurrence, then the Register shall be automatically deemed updated to reflect such occurrence.

(d)

Limitations on Conversions.

(i)

Beneficial Ownership. The Company shall not effect the conversion of any portion of this Note, and the Holder shall not have the

right to convert any portion of this Note pursuant to the terms and conditions of this Note and any such conversion shall be null and

void and treated as if never made, to the extent that after giving effect to such conversion, the Holder together with the other Attribution

Parties collectively would beneficially own in excess of 4.99% (the “Maximum Percentage”) of the Common Stock outstanding

immediately after giving effect to such conversion. For purposes of the foregoing sentence, the aggregate number of shares of Common

Stock beneficially owned by the Holder and the other Attribution Parties shall include the number of shares of Common Stock held by the

Holder and all other Attribution Parties plus the number of shares of Common Stock issuable upon conversion of this Note with respect

to which the determination of such sentence is being made, but shall exclude Common Stock which would be issuable upon (A) conversion

of the remaining, nonconverted portion of this Note beneficially owned by the Holder or any of the other Attribution Parties and (B)

exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation,

any convertible notes or convertible preferred stock or warrants) beneficially owned by the Holder or any other Attribution Party subject

to a limitation on conversion or exercise analogous to the limitation contained in this Section 3(d)(i). For purposes of this Section

3(d)(i), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act. For purposes of determining the

number of outstanding Common Stock the Holder may acquire upon the conversion of this Note without exceeding the Maximum Percentage,

the Holder may rely on the number of outstanding Common Stock as reflected in (x) the Company’s most recent Annual Report on Form

10-K, Report on Form 8-K or other public filing with the SEC, as the case may be, (y) a more recent public announcement by the Company

or (z) any other written notice by the Company or the Transfer Agent, if any, setting forth the number of shares of Common Stock outstanding

(the “Reported Outstanding Share Number”). If the Company receives a Conversion Notice from the Holder at a time when

the actual number of outstanding Common Stock is less than the Reported Outstanding Share Number, the Company shall notify the Holder

in writing of the number of shares of Common Stock then outstanding and, to the extent that such Conversion Notice would otherwise cause

the Holder’s beneficial ownership, as determined pursuant to this Section 3(d)(i), to exceed the Maximum Percentage, the Holder

must notify the Company of a reduced number of shares of Common Stock to be purchased pursuant to such Conversion Notice. For any reason

at any time, upon the written or oral request of the Holder, the Company shall within one (1) Trading Day confirm orally and in writing

or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding Common

Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Note, by the

Holder and any other Attribution Party since the date as of which the Reported Outstanding Share Number was reported. In the event that

the issuance of Common Stock to the Holder upon conversion of this Note results in the Holder and the other Attribution Parties being

deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding Common Stock (as determined

under Section 13(d) of the Exchange Act), the number of shares so issued by which the Holder’s and the other Attribution Parties’

aggregate beneficial ownership exceeds the Maximum Percentage (the “Excess Shares”) shall be deemed null and void

and shall be cancelled ab initio, and the Holder shall not have the power to vote or to transfer the Excess Shares. For purposes of clarity,

the Excess Shares shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section 13(d)

or Rule 16a-1(a)(1) of the Exchange Act. No prior inability to convert this Note pursuant to this paragraph shall have any effect on

the applicability of the provisions of this paragraph with respect to any subsequent determination of convertibility. The provisions

of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 3(d)(i)

to the extent necessary to correct this paragraph (or any portion of this paragraph) which may be defective or inconsistent with the

intended beneficial ownership limitation contained in this Section 3(d)(i) or to make changes or supplements necessary or desirable to

properly give effect to such limitation. The Holder, upon notice to the Company, may increase or decrease the Maximum Percentage provisions

of this Section, provided that the Maximum Percentage in no event exceeds 9.99% of the number of shares of Common Stock outstanding immediately

after giving effect to the issuance of shares of Common Stock upon conversion of this Note held by the Holder, and the provisions of

this Section shall continue to apply. Any increase in the Maximum Percentage will not be effective until sixty-one (61) Calendar Days

after such notice is delivered to the Company. The limitation contained in this paragraph may not be waived and shall apply to a successor

holder of this Note.

(ii)

Exchange Cap. Notwithstanding anything to the contrary contained in this Note, unless and until Stockholder Approval is obtained,

the Company shall not issue any shares of Common Stock upon conversion of this Note to the extent that such issuance, when aggregated

with all other shares of Common Stock issued or issuable pursuant to the Transaction Documents, would exceed the Exchange Cap. Any portion

of this Note that is not convertible as a result of the operation of this Section shall remain outstanding and shall become convertible

at such time, if ever, as such conversion would no longer cause the Exchange Cap to be exceeded, or upon Stockholder Approval being obtained,

whichever occurs first.

RIGHTS UPON EVENT OF DEFAULT.

(a)

Event of Default. Each of the following events shall constitute an “Event of Default”:

(i)

the Company’s default under this Note or the other Transaction Documents, including a failure to pay to the Holder any amount of

Principal, Interest, any prepayment price or any other amount when and as due under this Note or the other Transaction Documents, it

being understood and agreed that any such failure to pay shall constitute an immediate Event of Default without any requirement of notice,

demand or cure period;

(ii)

any default by the Company or any of its Subsidiaries in the payment when due of any principal or interest on any Indebtedness (other

than this Note) in an aggregate outstanding principal amount in excess of $[●], or the occurrence of any event or condition that

results in, or that with the giving of notice or the passage of time, or both, would permit the holder or holders of such Indebtedness

(or any trustee or agent on behalf of such holder or holders) to accelerate the maturity of such Indebtedness prior to its stated maturity,

in each case without such default, event or condition having been cured or waived, or such Indebtedness having been discharged, within

any applicable cure period provided with respect thereto;

(iii)

the Company fails to issue Common Stock without any restrictive legend or to remove any restrictive legend on any certificate (including

by book entry) for any Common Stock issued to the Holder pursuant to this Note within three (3) Trading Days after (A) receipt by the

Company of an executed Conversion Notice or (B) if the Holder has shares with a restrictive legend upon the Holder’s written notice

to remove such legend, in either case together with an opinion of counsel to the Holder that no restrictive legend is required;

(iv)

a materially false or inaccurate certification by the Company as to whether any Event of Default has occurred;

(v)

the occurrence of a Public Information Failure;

(vi)

bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings for the relief of debtors shall be instituted

by or against the Company and, if instituted against the Company by a third party, shall not be dismissed within thirty (30) days of

their initiation;

(vii)

the commencement by the Company of a voluntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency,

reorganization or other similar law or of any other case or proceeding to be adjudicated a bankrupt or insolvent, or the consent by it

to the entry of a decree, order, judgment or other similar document in respect of the Company in an involuntary case or proceeding under

any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or to the commencement of any bankruptcy

or insolvency case or proceeding against it, or the filing by it of a petition or answer or consent seeking reorganization or relief

under any applicable federal, state or foreign law, or the consent by it to the filing of such petition or to the appointment of or taking

possession by a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Company of any substantial

part of its property, or the making by it of an assignment for the benefit of creditors, or the execution of a composition of debts,

or the occurrence of any other similar federal, state or foreign proceeding, or the admission by it in writing of its inability to pay

its debts generally as they become due, the taking of corporate action by the Company in furtherance of any such action or the taking

of any action by any Person to commence a Uniform Commercial Code foreclosure sale or any other similar action under federal, state or

foreign law; or

(viii)

the entry by a court of (i) a decree, order, judgment or other similar document in respect of the Company of a voluntary or involuntary

case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or (ii)

a decree, order, judgment or other similar document adjudging the Company as bankrupt or insolvent, or approving as properly filed a

petition seeking liquidation, reorganization, arrangement, adjustment or composition of or in respect of the Company under any applicable

federal, state or foreign law or (iii) a decree, order, judgment or other similar document appointing a custodian, receiver, liquidator,

assignee, trustee, sequestrator or other similar official of the Company of any substantial part of its property, or ordering the winding

up or liquidation of its affairs, and the continuance of any such decree, order, judgment or other similar document or any such other

decree, order, judgment or other similar document unstayed and in effect for a period of thirty (30) consecutive days;

(ix)

other than as specifically set forth in another clause of this Section 4(a), the Company breaches any representation or warranty in any

material respect (other than representations or warranties subject to materiality limitations, which may not be breached in any respect)

or any covenant or other term or condition of this Note or any other Transaction Document, except, in the case of a breach of a covenant

or other term or condition that is curable, only if such breach remains uncured for a period of ten (10) consecutive Trading Days;

(x)

or the Company shall deny in writing that it has any liability or obligation purported to be created under any Transaction Document,

subject to a cure period of ten (10) consecutive Trading Days;

(xi)

the Company shall fail to be current in its filings under the Securities Act of 1933, as amended, and the Exchange Act, including, without

limitation, any reports on Form 10-K for the fiscal year ending on December 31, 2025;

(xii)

the Common Stock shall be delisted from the Principal Market or suspended from the Principal Market and such suspension shall continue

for more than five (5) consecutive Trading Days;

(xiii)

the Company replaces, removes, terminates or fails to maintain its transfer agent, or appoints any successor or additional transfer agent

that is not a participant in good standing in the DTC Fast Automated Securities Transfer Program;

(xiv)

the occurrence of any Material Adverse Effect; provided, however, that such Material Adverse Effect shall constitute an Event of Default

under this clause (xiv) only if it materially impairs the Company’s ability to conduct its business in the ordinary course or impairs

the Company’s ability to pay or perform its obligations under this Note when and as due;

(xv)

the Company fails at any time to reserve and keep available out of its authorized and unissued Common Stock the full number of shares

of Common Stock required to be reserved pursuant to Section 8;

(xvi)

the Company’s transfer agent ceases to participate in, or the Common Stock cease to be eligible for, the DTC Fast Automated Securities

Transfer Program or processing through the Deposit/Withdrawal at Custodian system, or the Common Stock otherwise cease to be eligible

for deposit at, or become subject to any restriction, “chill” or freeze imposed by, The Depository Trust Company, subject

to a cure period of ten (10) consecutive Trading Days.

(b)

Notice of an Event of Default. Upon the occurrence of an Event of Default with respect to this Note, the Company shall immediately,

and in no event more than one (1) Calendar Day of its discovery of such Event of Default, deliver written notice thereof via electronic

mail to the Holder.

(c)

Remedies. Immediately upon the occurrence of any Event of Default, the outstanding Principal of this Note shall automatically

be increased by twenty percent (20%) (the “Default Principal Increase”), without any further action by the Holder

or the Company, and such increased amount shall thereafter constitute Principal for all purposes of this Note (including, without limitation,

accrual of Default Interest under Section 2). The Default Principal Increase shall be in addition to, and not in lieu of, the Default

Interest payable under Section 2 and any other rights or remedies available to the Holder. Upon the occurrence of an Event of Default

and at any time thereafter, Holder may at its option: (a) declare the entire Principal Amount, together with all accrued Interest thereon,

immediately due and payable, and (b) exercise any or all of its rights, powers, or remedies under the Transaction Documents or applicable

law or available in equity. All rights and remedies of the Holder under this Note and the other Transaction Documents, at law and in

equity, are cumulative and not alternative, and the exercise of any one right or remedy shall not preclude the exercise of any other.

The Company shall reimburse the Holder for all costs of collection and enforcement (including reasonable attorneys’ fees and expenses)

incurred by the Holder in connection with any Event of Default or any breach by the Company of this Note or any other Transaction Document.

ADJUSTMENTS OF THE CONVERSION PRICE.

(a)

Adjustments for Recapitalization. If at any time or from time to time there shall be a recapitalization of the Common Stock, provision

shall be made so that the Holder shall thereafter be entitled to receive upon conversion of the Note the number of shares of stock or

other securities or property of the Company or otherwise, to which a holder of Common Stock deliverable upon conversion would have been

entitled on such recapitalization. In any such case, appropriate adjustment shall be made in the application of the provisions of this

Section 5(a) with respect to the rights of the Holder after the recapitalization to the end that the provisions of this Section 5(a)

(including, without limitation, provisions for adjustments of the Conversion Price and the number of shares of Common Stock issuable

upon conversion of the Note) shall be applicable after that event as nearly equivalent as may be practicable.

(b)

Adjustment for Stock Splits and Combinations. If the Company shall at any time or from time to time after the Issuance Date effect

a subdivision of the outstanding Common Stock, the Conversion Price in effect immediately before that subdivision shall be proportionately

decreased so that the number of shares of Common Stock issuable on conversion of this Note shall be increased in proportion to such increase

in the aggregate number of shares of Common Stock outstanding. If the Company shall at any time or from time to time after the Issuance

Date combine the outstanding Common Stock, the Conversion Price in effect immediately before the combination shall be proportionately

increased so that the number of shares of Common Stock issuable on conversion of the Note shall be decreased in proportion to such decrease

in the aggregate number of shares of Common Stock outstanding. Any adjustment under this subsection shall become effective at the close

of business on the date the subdivision or combination becomes effective.

(c)

Calculations. All calculations under this Section 5 shall be made by rounding to the nearest cent or the nearest 1/100th

of a share, as applicable. The number of shares of Common Stock outstanding at any given time shall not include shares owned or held

by or for the account of the Company, and the disposition of any such shares shall be considered an issue or sale of Common Stock.

(d)

Voluntary Adjustment by Company. The Company may at any time during the term of this Note, with the prior written consent of the

Holder, reduce the then current Conversion Price of the Note to any amount and for any period of time deemed appropriate by the board

of directors of the Company; provided that in no event shall the Conversion Price be reduced below the par value of the Common Stock.

NONCIRCUMVENTION. The Company hereby covenants and agrees that the Company will not, by amendment of the Company’s Certificate

of Incorporation or other charter documents, bylaws or through any reorganization, transfer of assets, consolidation, merger, dissolution,

issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms

of this Note or the other Transaction Documents, and will at all times in good faith carry out all of the provisions of this Note and

the other Transaction Documents and take all action as may be required to protect the rights of the Holder of this Note. Without limiting

the generality of the foregoing or any other provision of this Note or the other Transaction Documents, the Company (a) shall not increase

the par value of any Common Stock receivable upon conversion of this Note above the Conversion Price then in effect, and (b) shall take

all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable

Common Stock upon the conversion of this Note. In addition, for so long as any portion of this Note remains outstanding, the Company

shall not, directly or indirectly, declare, pay, set aside or make, or agree to declare, pay, set aside or make, any dividend or other

distribution (whether in cash, securities, property or otherwise) on, or any redemption, repurchase or other acquisition of, any of its

Common Stock or other equity securities, in each case without the prior written consent of the Holder, except for in connection with

any reverse share split effected in order to bring the Company into compliance with the applicable listing rules of the Principal Market.

VARIABLE RATE TRANSACTION PROTECTION.

(a)

For so long as any portion of the Note remains outstanding, the Company shall not, directly or indirectly, issue, offer, sell, grant

any option or right to purchase, or otherwise dispose of (or announce any issuance, offer, sale, grant of any option or right to purchase,

or other disposition of) any equity security or equity-linked security, including any debt, preferred shares or other instrument or security

that is, at any time during its life and under any circumstances, convertible into or exercisable or exchangeable for Common Stock or

Common Stock Equivalents, at a conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading

prices of, or quotations for, Common Stock at any time after the initial issuance of such debt, preferred shares or other instrument

or security, or with a floating conversion, exercise or exchange price or a conversion, exercise or exchange price subject to being reset

at some future date after the initial issuance of such debt, preferred shares or other instrument or security, or that is subject to

or may be adjusted as a result of a subsequent issuance or offering of Common Stock or Common Stock Equivalents, including by way of

one or more reset(s) to a fixed price, or that is subject to or contains any put, call, redemption, buy-back, price-reset or other similar

provision or mechanism (including, without limitation, a “Black-Scholes” put or call right) that provides for the issuance

of additional equity securities of the Company or the payment of cash by the Company, and any of the foregoing offerings or issuances

(any such security or agreement, a “Variable Rate Transaction”); provided, however, that (x) neither

the Warrants nor the issuance of Common Stock thereunder shall constitute a Variable Rate Transaction, and (y) the existing agreement

with CP BF Lending in effect as of the Issuance Date, as amended, restated, refinanced or replaced (each, an “Existing VRT”)

shall not constitute a Variable Rate Transaction for purposes of this Section 7(a). In addition, for so long as any portion of the Note

remains outstanding, the Company shall not have in force and effect any Variable Rate Transaction other than any Existing VRT (including

the continuation, but not the amendment, modification or extension of any Existing VRT in any manner that would increase the amounts

payable thereunder, extend the term thereof, or otherwise increase the obligations of the Company or expand the rights of the holder

thereof).

(b)

The Company and the Holder acknowledge that the actual damages likely to result from the Company’s entry into a Variable Rate Transaction

in breach of Section 7(a), including from the resulting dilutive impact and loss of exclusivity value, are difficult to ascertain with

precision, such that the amount set forth in this Section 7(b) represents the Parties’ reasonable good-faith estimate of such damages

and not a penalty. Accordingly, upon such aforementioned breach of Section 7(a), then the Company shall pay the Holder $250,000, as liquidated

damages and not a penalty, with respect to each such Variable Rate Transaction, where such liquidated damages shall be payable, at the

Company’s election, either with Common Stock (where such Common Stock shall be delivered by the Company to the Holder as reasonably

instructed by the Holder) or the lawful money of the U.S. by wire transfer of immediately available funds to such account as the Holder

may designate from time to time) within three (3) Business Days of the earlier of (x) the Company’s entry into such Variable Rate

Transaction, or (y) the Holder’s actual knowledge thereof; accordingly, the Company shall provide the Holder with written notice

of the Company’s entry into any Variable Rate Transaction within one (1) Business Day thereof (and such notice shall include providing

the Holder with a copy of the agreements entered into by the Company in connection with such Variable Rate Transaction). The payment

by the Company of this liquidated damages amount shall be in addition to all other obligations of the Company set forth in the Transaction

Documents to which the Company is a party, and shall similarly be in addition to all the rights and remedies enjoyed by the Holder in

the Transaction Documents, and shall not serve to waive, limit, proscribe, mitigate, reduce or in any way impede the other rights and

remedies enjoyed by the Holder, including, but not limited to, the right to seek injunctive relief set forth in Section 7(c).

(c)

The Holder shall be entitled to seek specific performance and/or injunctive relief, whether preliminary or permanent, against the Company

to preclude any actual or threatened Variable Rate Transaction, which remedy shall be in addition to, and not in lieu of, any right to

collect damages under Section 7(b) or otherwise. The Company acknowledges and agrees that any breach or threatened breach of Section

7(a) would cause the Holder irreparable harm for which monetary damages would not be an adequate remedy, notwithstanding the availability

of the liquidated damages payable pursuant to Section 7(b), which the Company and Holder agree addresses a distinct component of the

harm arising from such a breach and does not fully compensate the Holder for the harm caused by the actual or continued existence of

a Variable Rate Transaction. The Company reserves all defenses otherwise available to it in any such action.

RESERVATION OF AUTHORIZED SHARES. So long as the Note remains outstanding, the Company shall at all times reserve at least 300%

of the number of shares of Common Stock as shall from time to time be necessary to effect the conversion of the Note then outstanding

(without regard to any limitations on conversions and assuming such Note remains outstanding until the Maturity Date) at the Conversion

Price then in effect.

PREPAYMENT. Subject to the Holder’s right to convert the Note pursuant to Section 3, the Company may, upon not less than

five (5) Trading Days’ prior written notice to the Holder (during which period the Holder may elect to convert any or all of the

outstanding Principal and accrued Interest), prepay all or any portion of the Outstanding Amount at a price equal to 110% of the portion

of the Outstanding Amount so prepaid. As used in this Note, the “Outstanding Amount” means, as of any date of determination,

the sum of (i) the then-outstanding Principal, plus (ii) all accrued and unpaid Interest thereon through such date, plus (iii) all other

amounts then due and owing under this Note and the other Transaction Documents (including, without limitation, any Default Principal

Increase, any accrued and unpaid Default Interest, any liquidated damages and any costs, fees and expenses reimbursable to the Holder).

10.

MANDATORY PREPAYMENT FROM FUTURE CAPITAL RAISES.

(a)

If, at any time while any portion of this Note remains outstanding, the Company (or any of its subsidiaries) consummates any financing

or capital raise (whether through the issuance of debt, equity, equity-linked securities or any combination thereof, and whether in a

public offering, private placement, registered direct offering, PIPE, at-the-market offering or otherwise) (each, a “Subsequent

Financing”), then, unless such Subsequent Financing constitutes a Qualified Public Offering, the Company shall apply, at the

closing of such Subsequent Financing and prior to the Company’s receipt of any net proceeds thereof, fifty percent (50%) of the

net cash proceeds actually received by the Company from such Subsequent Financing to the prepayment of the outstanding Principal and

accrued and unpaid Interest of this Note at a price equal to 100% of the sum of (i) the Principal so prepaid plus (ii) all accrued and

unpaid Interest thereon through the prepayment date plus (iii) all other amounts then due and owing under this Note and the other Transaction

Documents in respect of the portion so prepaid (including, without limitation, any Default Principal Increase, any accrued and unpaid

Default Interest, any liquidated damages and any costs, fees and expenses reimbursable to the Holder). The Company shall provide the

Holder with prior written notice of any Subsequent Financing not later than two (2) Trading Days prior to the closing thereof, together

with reasonable detail regarding the net cash proceeds and material terms of such Subsequent Financing. The Holder may, by written notice

delivered to the Company at any time prior to the closing of a Subsequent Financing, elect to have all or any portion of the amounts

payable under this Section 10(a) satisfied directly out of the net cash proceeds of such Subsequent Financing at the closing thereof,

in which case the Company shall cause such amounts to be paid to the Holder by wire transfer of immediately available funds concurrently

with, and as a condition to, the closing of such Subsequent Financing. Any amounts payable under this Section 10(a) that are not so satisfied

at such closing shall be paid in cash by wire transfer of immediately available funds to an account designated in writing by the Holder

within two (2) Trading Day following the Holder’s written demand. This Section 10(a) is in addition to, and not in lieu of, any

other rights or remedies of the Holder under this Note or the other Transaction Documents (including, without limitation, the Holder’s

conversion rights under Section 3). For the avoidance of doubt, nothing in this Section 10(a) shall be deemed to permit the Company to

solicit, negotiate, enter into or consummate any Subsequent Financing that is otherwise prohibited by, or that requires the prior consent,

approval or waiver of the Holder under, this Note or any other Transaction Document (including, without limitation, any standstill or

restriction on the Company’s incurrence of indebtedness or issuance of securities), and the Company’s obligations under this

Section 10(a) apply in addition to, and not in limitation of, any such restriction or consent, approval or waiver requirement.

(b)

Mandatory Acceleration Upon Qualified Public Offering. Upon the consummation of a Qualified Public Offering, the Maturity Date of this

Note shall automatically be accelerated to the closing date on which the Qualified Public Offering is deemed consummated pursuant to

the definition thereof, and the entire outstanding Principal amount of this Note, together with all accrued and unpaid Interest thereon

and all other amounts then due and owing under this Note and the other Transaction Documents (including, without limitation, any Default

Principal Increase, any accrued and unpaid Default Interest, any liquidated damages and any costs, fees and expenses reimbursable to

the Holder), shall become immediately due and payable in full, in cash, at such closing, subject to the Holder’s right to convert

this Note, in whole or in part, at any time prior to such closing pursuant to Section 3. The Company shall provide the Holder with prior

written notice promptly upon (and in any event within one (1) Trading Day after) the Company’s execution of an underwriting agreement,

placement agency agreement or similar agreement with respect to a proposed Qualified Public Offering, together with reasonable detail

regarding the anticipated gross proceeds and material terms of such offering, and shall provide the Holder with prompt written notice

of the actual gross proceeds received at each closing thereof. This Section 10(b) is in addition to, and not in lieu of, any other rights

or remedies of the Holder under this Note or the other Transaction Documents..

11.

AMENDING THE TERMS OF THIS NOTE. The prior written consent of the Holder shall be required for any change, waiver or amendment

to this Note. Any change, waiver or amendment so approved shall be binding upon all existing and future holders of this Note; provided,

however, that no such change, waiver, or amendment, as applied to the Note held by any particular holder of the Note, shall, without

the written consent of that particular holder, (i) reduce the amount of Principal, reduce the amount of accrued and unpaid Interest,

or extend the Maturity Date, of the Note, (ii) disproportionally and adversely affect any rights under the Note of that particular holder;

or (iii) modify any of the provisions of, or impair the right of any holder of the Note under this Section 11.

12.

REISSUANCE OF THIS NOTE.

(a)

Transfer. If this Note is to be transferred, the Holder shall surrender this Note to the Company, whereupon the Company will forthwith

issue and deliver upon the order of the Holder a new Note (in accordance with Section 12(d)), registered as the Holder may request, representing

the outstanding Principal being transferred by the Holder and, if less than the entire outstanding Principal is being transferred, a

new Note (in accordance with Section 12(d)) to the Holder representing the outstanding Principal not being transferred. The Holder and

any assignee, by acceptance of this Note, acknowledge and agree that, by reason of the provisions of Section 3(c)(iii) following conversion

or prepayment of any portion of this Note, the outstanding Principal represented by this Note may be less than the Principal stated on

the face of this Note.

(b)

Lost, Stolen or Mutilated Note. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft,

destruction or mutilation of this Note (as to which a written certification and the indemnification contemplated below shall suffice

as such evidence), and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Company in

customary and reasonable form and, in the case of mutilation, upon surrender and cancellation of this Note, the Company shall execute

and deliver to the Holder a new Note (in accordance with Section 12(d)) representing the outstanding Principal.

(c)

Note Exchangeable for Different Denominations. This Note is exchangeable, upon the surrender hereof by the Holder at the principal

office of the Company, for a new Note or Notes (in accordance with Section 12(d) and in principal amounts of at least $1,000) representing

in the aggregate the outstanding Principal of this Note, and each such new Note will represent such portion of such outstanding Principal

as is designated by the Holder at the time of such surrender.

(d) Issuance

of New Notes. Whenever the Company is required to issue a new Note pursuant to the terms of this Note, such new Note (i) shall

be of like tenor with this Note, (ii) shall represent, as indicated on the face of such new Note, the Principal remaining

outstanding (or in the case of a new Note being issued pursuant to Section 12(a) or Section 12(c), the Principal designated by the

Holder which does not exceed the Principal remaining outstanding under this Note immediately prior to such issuance of a new Note),

(iii) shall have an issuance date, as indicated on the face of such new Note, which is the same as the Issuance Date of this Note,

(iv) shall have the same rights and conditions as this Note, and (v) shall represent accrued and unpaid Interest.

13.

COVENANTS.

(a)

Rank. All payments due under this Note shall be (i) subordinate and junior in right of payment and priority to all secured Indebtedness

of the Company existing as of the Issuance Date and (ii) senior to all other Indebtedness of the Company.

(b)

Restricted Payments and Investments. The Company shall not, and the Company shall cause each of its Subsidiaries to not, directly

or indirectly, redeem, defease, repurchase, repay, or make any payments in respect of, by the payment of cash or cash equivalents (in

whole or in part, whether by way of open market purchases, tender offers, private transactions, or otherwise), all or any portion of

any Indebtedness (other than the Note) whether by way of payment in respect of principal of (or premium, if any) or interest on, such

Indebtedness or make any Investment, as applicable, if at the time such payment with respect to such Indebtedness and/or Investment,

as applicable, is due or is otherwise made or, after giving effect to such payment, (i) an event constituting an Event of Default has

occurred and is continuing, or (ii) an event that with the passage of time and without being cured would constitute an Event of Default

has occurred and is continuing.

(c)

Restriction on Redemption and Cash Dividends. The Company shall not, and the Company shall cause each of its Subsidiaries to not,

directly or indirectly, redeem, repurchase for cash any of its capital stock, or declare or pay any cash dividend or distribution on

any of its capital stock.

(d)

Restriction on Transfer of Assets. The Company shall not, and the Company shall cause each of its Subsidiaries to not, directly

or indirectly, sell, lease, license, assign, transfer, spin-off, split-off, close, convey, or otherwise dispose of any assets or rights

of the Company or any Subsidiary owned or hereafter acquired whether in a single transaction or a series of related transactions, other

than (i) sales, leases, licenses, assignments, transfers, conveyances, and other dispositions of such assets or rights by the Company

and its Subsidiaries in the ordinary course of business consistent with its past practice, and (ii) sales of inventory and product in

the ordinary course of business.

(e)

Change in Nature of Business. The Company shall not, and the Company shall cause each of its Subsidiaries to not, directly or

indirectly, engage in any material line of business substantially different from those lines of business conducted by or publicly contemplated

to be conducted by the Company and each of its Subsidiaries on the Issuance Date or any business substantially related or incidental

thereto. The Company shall not, and the Company shall cause each of its Subsidiaries to not, directly or indirectly, modify its or their

corporate structure or purpose.

(f)

Preservation of Existence, Etc. The Company shall maintain and preserve, and cause each of its Subsidiaries to maintain and preserve,

its existence, rights, and privileges, and become or remain, and cause each of its Subsidiaries to become or remain, duly qualified and

in good standing in each jurisdiction in which the character of the properties owned or leased by it or in which the transaction of its

business makes such qualification necessary.

(g)

Maintenance of Properties, Etc. The Company shall maintain and preserve, and cause each of its Subsidiaries to maintain and preserve,

all of its properties which are necessary or useful in the proper conduct of its business in good working order and condition, ordinary

wear and tear excepted, and comply, and cause each of its Subsidiaries to comply, at all times with the provisions of all leases to which

it is a party as lessee or under which it occupies property, so as to prevent any loss or forfeiture thereof or thereunder.

(h)

Maintenance of Intellectual Property. The Company will, and will cause each of its Subsidiaries to, take all action necessary

or advisable to maintain all of the Intellectual Property Rights of the Company and/or any of its Subsidiaries that are necessary or

material to the conduct of its business in full force and effect.

(i)

Maintenance of Insurance. The Company shall maintain, and cause each of its Subsidiaries to maintain, insurance with responsible

and reputable insurance companies or associations (including, without limitation, comprehensive general liability, hazard, rent, and

business interruption insurance) with respect to its properties (including all real properties leased or owned by it) and business, in

such amounts and covering such risks as is required by any governmental authority having jurisdiction with respect thereto or as is carried

generally in accordance with sound business practice by companies in similar businesses similarly situated (but in no event including

less than $1,000,000.00 of director and officer insurance).

(j)

Transactions with Affiliates. The Company shall not, nor shall it permit any of its Subsidiaries to, enter into, renew, extend

or be a party to, any transaction or series of related transactions (including, without limitation, the purchase, sale, lease, transfer,

or exchange of property or assets of any kind or the rendering of services of any kind) with any affiliate, except (i) transactions in

the ordinary course of business in a manner and to an extent consistent with past practice and necessary or desirable for the prudent

operation of its business, for fair consideration and on terms no less favorable to it or its Subsidiaries than would be obtainable in

a comparable arm’s length transaction with a Person that is not an affiliate thereof, and (ii) the purchase by Joseph Davy of shares

of Class B common stock of the Company.

(k)

Stay, Extension, and Usury Laws. To the extent that it may lawfully do so, the Company (A) agrees that it will not at any time

insist upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension, or usury law (wherever

or whenever enacted or in force) that may affect the covenants or the performance of this Note; and (B) expressly waives all benefits

or advantages of any such law and agrees that it will not, by resort to any such law, hinder, delay, or impede the execution of any power

granted to the Holder by this Note, but will suffer and permit the execution of every such power as though no such law has been enacted.

(l)

Taxes. The Company and its Subsidiaries shall pay when due all taxes, fees, or other charges of any nature whatsoever (together

with any related interest or penalties) now or hereafter imposed or assessed against the Company and its Subsidiaries or their respective

assets or upon their ownership, possession, use, operation, or disposition thereof or upon their rents, receipts, or earnings arising

therefrom (except where the failure to pay would not, individually or in the aggregate, have a material effect on the Company or any

of its Subsidiaries). The Company and its Subsidiaries shall file on or before the due date therefor all personal property tax returns

(except where the failure to file would not, individually or in the aggregate, have a material effect on the Company or any of its Subsidiaries).

Notwithstanding the foregoing, the Company and its Subsidiaries may contest, in good faith and by appropriate proceedings, taxes for

which they maintain adequate reserves therefor in accordance with GAAP.

14.

CONSTRUCTION; HEADINGS. This Note shall be deemed to be jointly drafted by the Company and the initial Holder and shall not be

construed against any such Person as the drafter hereof. The headings of this Note are for convenience of reference and shall not form

part of, or affect the interpretation of, this Note. Unless the context clearly indicates otherwise, each pronoun herein shall be deemed

to include the masculine, feminine, neuter, singular and plural forms thereof. The terms “including,” “includes,”

“include” and words of like import shall be construed broadly as if followed by the words “without limitation.”

The terms “herein,” “hereunder,” “hereof” and words of like import refer to this entire Note instead

of just the provision in which they are found. Unless expressly indicated otherwise, all section references are to sections of this Note.

Terms used in this Note and not otherwise defined herein, but defined in the other Transaction Documents, shall have the meanings ascribed

to such terms on the closing date in such other Transaction Documents unless otherwise consented to in writing by the Holder.

15.

FAILURE OR INDULGENCE NOT WAIVER. No failure or delay on the part of the Holder in the exercise of any power, right or privilege

hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude

other or further exercise thereof or of any other right, power or privilege. No waiver shall be effective unless it is in writing and

signed by an authorized representative of the waiving party.

16.

NOTICES. Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be given

in writing with an e-mail copy to the last address provided by the Holder or its agents in writing to the Company. The Company shall

provide the Holder with prompt written notice of all actions taken pursuant to this Note, including in reasonable detail a description

of such action and the reason therefor. Without limiting the generality of the foregoing, the Company will give written notice to the

Holder (i) immediately upon any adjustment of the Conversion Price, setting forth in reasonable detail, and certifying, the calculation

of such adjustment and (ii) at least 15 days prior to the date on which the Company closes its books or takes a record (A) with respect

to any dividend or distribution upon the Common Stock, to which the Holder has consented pursuant to Section 6, or (B) for determining

rights to vote with respect to any transaction, dissolution or liquidation, provided in each case that such information shall be made

known to the public prior to or in conjunction with such notice being provided to the Holder.

17.

WAIVER OF NOTICE. To the extent permitted by law, the Company hereby irrevocably waives demand, notice, presentment, protest and

all other demands and notices in connection with the delivery, acceptance, performance, default or enforcement of this Note.

18.

GOVERNING LAW. This Note shall be construed and enforced in accordance with, and all questions concerning the construction,

validity, interpretation and performance of this Note shall be governed by, the internal laws of the State of Delaware, without giving

effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdictions) that would

cause the application of the laws of any jurisdictions other than the State of Delaware. Each party agrees that all legal proceedings

concerning the interpretation, enforcement and defense of the transactions contemplated by this Note (whether brought against a party

hereto or its respective Affiliates, directors, officers, stockholders, employees or agents) shall be commenced exclusively in the state

and federal courts sitting in the State of Delaware. Each party hereby irrevocably submits to the exclusive jurisdiction of such courts

for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein,

and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject

to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.

Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding

by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address

in effect for notices to it under this Note and agrees that such service shall constitute good and sufficient service of process and

notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted

by law. If any party commences an action or proceeding to enforce any provisions of this Note, then the prevailing party in such action

or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred in

the investigation, preparation and prosecution of such action or proceeding. In the event that any provision of this Note is invalid

or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may

conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid

or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement.

19.

DISPUTE RESOLUTION.

(a)

Submission to Dispute Resolution.

(i)

In the case of a dispute relating to the Conversion Price, a fair market value, or the arithmetic calculation of a Conversion Rate (as

the case may be) (including, without limitation, a dispute relating to the determination of any of the foregoing), the Company or the

Holder (as the case may be) shall submit the dispute to the other party via electronic mail (A) if by the Company, within five (5) Business

Days after the occurrence of the circumstances giving rise to such dispute or (B) if by the Holder at any time after the Holder learned

of the circumstances giving rise to such dispute. If the Holder and the Company are unable to promptly resolve such dispute relating

to such Conversion Price, such fair market value, or the arithmetic calculation of such Conversion Rate (as the case may be) (as the

case may be), at any time after the fifth (5th) Business Day following such initial notice by the Company or the Holder (as the case

may be) of such dispute to the Company or the Holder (as the case may be), then the Company and the Holder may select an independent,

reputable investment bank as mutually agreed upon to resolve such dispute. If the parties cannot agree upon such an investment bank within

ten (10) Business Days of the date of the initial notice, the parties shall apply to the Chancery Court of the State of Delaware and

the United States District Court for the District of Delaware for the appointment of an arbitrator.

(ii)

The Holder and the Company shall each deliver to such investment bank (or arbitrator) (A) a copy of the initial dispute submission so

delivered in accordance with the first sentence of this Section 19 and (B) written documentation supporting its position with respect

to such dispute, in each case, no later than 5:00 p.m. (New York time) by the fifth (5th) Business Day immediately following the date

on which the Holder selected such investment bank (the “Dispute Submission Deadline”) (the documents referred to in

the immediately preceding clauses (A) and (B) are collectively referred to herein as the “Required Dispute Documentation”)

(it being understood and agreed that if either the Holder or the Company fails to so deliver all of the Required Dispute Documentation

by the Dispute Submission Deadline, then the party who fails to so submit all of the Required Dispute Documentation shall no longer be

entitled to (and hereby waives its right to) deliver or submit any written documentation or other support to such investment bank (or

arbitrator) with respect to such dispute and such investment bank shall resolve such dispute based solely on the Required Dispute Documentation

that was delivered to such investment bank (or arbitrator) prior to the Dispute Submission Deadline). Unless otherwise agreed to in writing

by both the Company and the Holder or otherwise requested by such investment bank (or arbitrator), neither the Company nor the Holder

shall be entitled to deliver or submit any written documentation or other support to such investment bank (or arbitrator) in connection

with such dispute (other than the Required Dispute Documentation).

(iii)

The Company and the Holder shall cause such investment bank (or arbitrator) to determine the resolution of such dispute and notify the

Company and the Holder of such resolution no later than ten (10) Business Days immediately following the Dispute Submission Deadline.

The fees and expenses of such investment bank (or arbitrator) shall be borne by the losing party, and such investment bank’s (or

arbitrator’s) resolution of such dispute shall be final and binding upon all parties absent manifest error.

(b)

Miscellaneous. The Company expressly acknowledges and agrees that (i) this Section 19 constitutes an agreement to arbitrate between

the Company and the Holder (and constitutes an arbitration agreement) under § 5701, et seq. of the Delaware Code Title 10) and that

both the Company and the Holder are authorized to apply for an order to compel arbitration pursuant to Delaware Code Title 10 §

5703 in order to compel compliance with this Section 19, (ii) the terms of this Note and each other applicable Transaction Document shall

serve as the basis for the selected investment bank’s resolution of the applicable dispute, such investment bank shall be entitled

(and is hereby expressly authorized) to make all findings, determinations, and the like that such investment bank determines are required

to be made by such investment bank in connection with its resolution of such dispute and in resolving such dispute such investment bank

shall apply such findings, determinations and the like to the terms of this Note and any other applicable Transaction Documents, and

(iii) nothing in this Section 19 shall limit the Holder or the Company from obtaining any injunctive relief or other equitable remedies

(including, without limitation, with respect to any matters described in this Section 19).

20.

SEVERABILITY. If any provision of this Note is prohibited by law or otherwise determined to be invalid or unenforceable by a court

of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply

to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect

the validity of the remaining provisions of this Note so long as this Note as so modified continues to express, without material change,

the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the

provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical

realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations

to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible

to that of the prohibited, invalid or unenforceable provision(s).

21.

MAXIMUM PAYMENTS. Nothing contained herein shall be deemed to establish or require the payment of a rate of interest or other

charges in excess of the maximum permitted by applicable law. In the event that the rate of interest required to be paid or other charges

hereunder exceed the maximum permitted by such law, any payments in excess of such maximum shall be credited against amounts owed by

the Company to the Holder and thus refunded to the Company.

22.

ASSIGNMENT. Neither this Note nor the rights contained herein may be assigned, by operation of law or otherwise, by either party

without the prior written consent of the other; provided, however, that this Note and/or the rights contained herein may be assigned

without the Company’s consent by the Holder to any other entity who controls, is controlled by or is under common control with

the Holder.

23.

CERTAIN DEFINITIONS. For purposes of this Note, the following words and terms shall have the following meanings:

(a)

“Attribution Parties” means, collectively, the following Persons and entities: (i) any investment vehicle, including,

any funds, feeder funds or managed accounts, currently, or from time to time after the Issuance Date, directly or indirectly managed

or advised by the Holder’s investment manager or any of its affiliates or principals, (ii) any direct or indirect affiliates of

the Holder or any of the foregoing, (iii) any Person acting or who could be deemed to be acting as a “group” (as that term

is used in Section 13(d) of the Exchange Act) together with the Holder or any of the foregoing and (iv) any other Persons whose beneficial

ownership of the Company’s Common Stock would or could be aggregated with the Holder’s and the other Attribution Parties

for purposes of Section 13(d) of the Exchange Act. For clarity, the purpose of the foregoing is to subject collectively the Holder and

all other Attribution Parties to the Maximum Percentage, for each Conversion Notice tendered to the Company.

(b)

“Business Day” means a Calendar Day other than a Saturday, Sunday or any other Calendar Day which is a federal legal

holiday in the United States or any Calendar Day on which the commercial banks in the City of New York are required by law or other governmental

action to close, provided that the commercial banks in the City of New York shall not be deemed to be required to be closed due to a

“stay at home,” “shelter in place,” “non-essential employee” or similar orders or restrictions or

the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer

systems (including for wire transfers) of commercial banks in the City of New York generally are open for use by customers on such Calendar

Day.

(c)

“Calendar Day” means each and every day of the week (Sunday, Monday, Tuesday, Wednesday, Thursday, Friday and Saturday).

(d)

“Common Stock” means the Class A common stock of the Company, $0.0001 par value per share, and any other class of

securities into which such securities may hereafter be reclassified or changed.

(e)

“Exchange Cap” means, unless and until Stockholder Approval is obtained, a number of shares of Common Stock equal

to nineteen and ninety-nine hundredths percent (19.99%) of the shares of Common Stock issued and outstanding immediately prior to the

execution of the Securities Purchase Agreement (subject to equitable adjustment for any stock split, stock dividend, stock combination,

recapitalization or similar transaction affecting the Common Stock after the date hereof), reduced by the aggregate number of shares

of Common Stock issued or issuable pursuant to the other Transaction Documents.

(f)

“Investment” means any beneficial ownership (including stock, partnership or limited liability company interests)

of or in any Person, or any loan, advance, or capital contribution to any Person or the acquisition of all, or substantially all, of

the assets of another Person or the purchase of any assets of another Person for greater than the fair market value of such assets.

(g)

“Material Adverse Effect” shall have the meaning set forth in the Securities Purchase Agreement; provided, however,

that such Material Adverse Effect shall constitute an Event of Default under this clause (xiv) only if it materially impairs (x) the

Company’s ability to conduct its business in the ordinary course or (y) the Company’s ability to pay or perform its obligations

under this Note when and as due..

(h)

“Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust,

an unincorporated organization, any other entity or a government or any department or agency thereof.

(i)

“Principal Market” means the Nasdaq Capital Market.

(j)

“Qualified Public Offering” means the closing of a public offering of the Company’s Common Stock (or other equity

or equity-linked securities) pursuant to an effective registration statement filed under the Securities Act of 1933, as amended, whether

such offering is underwritten on a firm commitment basis, underwritten on a best efforts basis, or sold through one or more placement

agents acting as agent for the Company (including, without limitation, a registered direct offering), in each case resulting in aggregate

gross proceeds to the Company, before deduction of underwriting discounts, commissions, placement agent fees and offering expenses, of

not less than $5,000,000. If such offering involves more than one closing (including, without limitation, a closing pursuant to the exercise

of an over-allotment option), the gross proceeds of all such closings shall be aggregated for purposes of determining whether the $5,000,000

threshold has been met, and the Qualified Public Offering shall be deemed to have been consummated upon the closing at which such aggregate

threshold is first satisfied.

(k)

“Securities Purchase Agreement” means that certain Securities Purchase Agreement, dated as of September 4, 2026, by

and among the Company, the Holder and the other purchasers party thereto.

(l)

“Stockholder Approval” means such approval as may be required by the applicable rules and regulations of The Nasdaq

Stock Market LLC (or any successor entity) from the stockholders of the Company, or board of directors in lieu thereof, with respect

to the issuance of the Conversion Shares upon conversion of this Note, including without limitation: (i) to issue in excess of twenty

percent (20%) of the outstanding shares of Common Stock at a deemed discount to the Nasdaq Minimum Price (as defined in Nasdaq Listing

Rule 5635(d)(1)(A)) immediately prior to execution of the Securities Purchase Agreement; (ii) to consent to the voluntary reduction of

the Conversion Price described in this Note; and (iii) to permit the issuance of shares of Common Stock under this Note and the other

Transaction Documents in excess of the Exchange Cap.

(m)

“Subsidiaries” means any Person in which the Company on the Issuance Date, directly or indirectly, (i) owns or acquires

at least a majority of the outstanding capital stock or holds any equity or similar interest of such Person having, by their terms, voting

power to elect a majority of the board of directors or others performing similar functions for such Person, (ii) is a general partner

or manager, or (iii) otherwise controls or operates all or substantially all of the business, operations, or administration of such Person.

(n)

“Trading Day” means, as applicable, (x) with respect to all price or trading volume determinations relating to the

Common Stock, any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the principal trading

market for the Common Stock, then the principal securities exchange or securities market on which the Common Stock is then traded, provided

that “Trading Day” shall not include any day on which the Common Stock is scheduled to trade on such exchange or market for

less than 4.5 hours or any day that the Common Stock is suspended from trading during the final hour of trading on such exchange or market

(or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the

hour ending at 4:00 p.m., New York time) unless such day is otherwise designated as a Trading Day in writing by the Holder or (y) with

respect to all determinations other than price determinations relating to the Common Stock, any day on which The Nasdaq Stock Market

LLC (or any successor thereto) is open for trading of securities.

(o)

“Transaction Documents” means this Note, the Securities Purchase Agreement, the Warrants, the Placement Agent Agreement,

the Lock-Up Agreement, and all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection

with the transactions contemplated hereunder.

[signature

page follows]

WITNESS WHEREOF, the Company has caused this Note to be duly executed as of the Issuance Date set out above.

BANZAI INTERNATIONAL, INC.

By:

Name:

Joseph Davy

Title:

Chief Executive Officer

EXHIBIT

BANZAI

INTERNATIONAL, INC.

CONVERSION

NOTICE

Reference

is made to the Convertible Promissory Note (the “Note”) issued to the undersigned by BANZAI INTERNATIONAL, INC., a

Delaware corporation (the “Company”). In accordance with and pursuant to the Note, the undersigned hereby elects to

convert the Conversion Amount (as defined in the Note) of the Note indicated below into Class A common stock, $0.0001 par value per share

(the “Common Stock”), of the Company, as of the date specified below. Capitalized terms not defined herein shall have

the meaning as set forth in the Note.

Date

of Conversion: _______________________________________________

Aggregate

Principal to be converted: _________________________________________________________

Aggregate

accrued and unpaid Interest to be converted: ___________________________________________

AGGREGATE

CONVERSION AMOUNT TO BE CONVERTED:

Please

confirm the following information:

Conversion

Price: ___________________________________________________________________________

Number

of shares of Common Stock to be issued: ___________________________________________________

Please

issue the Common Stock into which the Note is being converted to Holder, or for its benefit, as follows:

☐

Check here if requesting

delivery as a certificate to the following name and to the following address:

Issue to:

☐

Check here if requesting delivery by Deposit/Withdrawal

at Custodian as follows:

DTC

Participant: _____________________________________________________________________________

DTC

Number: _______________________________________________________________________________

Account

Number: ____________________________________________________________________________

Date:

____________,__________

Name of Registered Holder

By:

Name:

Title:

Tax ID:

Facsimile:

E-mail

Address:

EX-4.2

Filename: ex4-2.htm · Sequence: 3

Exhibit

4.2

NEITHER

THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION

OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED

(THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT

UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS

OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE

OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

PIPE

COMMON WARRANT TO PURCHASE COMMON STOCK

BANZAI

INTERNATIONAL, INC.

Warrant

Shares: 779,221

Initial

Exercise Date: September 4, 2026

Issuance

Date: September 4, 2026

THIS

WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, Evergreen Capital

Management LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on

exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date and on or prior to 5:00 p.m. (New

York City time) on the date that is the fifth anniversary of the Issuance Date (the “Termination Date”) but

not thereafter, to subscribe for and purchase from Banzai International, Inc., a Delaware corporation (the “Company”),

up to 779,221 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. Subject to

the provisions of Section 2.3, the purchase price of one (1) share of Common Stock under this Warrant shall be equal to the Exercise

Price, as defined in Section 2.2.

1. Definitions.

In addition to the terms defined elsewhere in this Warrant or in the Securities Purchase

Agreement dated September 4, 2026 by and among the Company and the investors (the “Purchasers”)

referred to therein (the “Securities Purchase Agreement”), the

following terms have the meanings indicated in this Section 1:

1.1.

“Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is

controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

1.2.

“Anti-Dilution Trigger Event” means the Company’s failure to pay all outstanding principal, accrued and

unpaid interest, and any other amounts then due and owing under the Note in full, in cash, on or before the date that is ninety (90)

calendar days after the date of the Initial Closing under the Securities Purchase Agreement.

1.3.

“Bid Price” means, for any date, the price determined by the first of the following clauses that applies:

(a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or

the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P.

(based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a

Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or

OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common

Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting

prices), the most recent bid price per share of Common Stock so reported, or (d) in all other cases, the fair market value of a

share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of

the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the

Company.

1.4.

“Board of Directors” means the board of directors of the Company.

1.5.

“Business Day” means a Calendar Day other than a Saturday, Sunday or any other Calendar Day which is a federal

legal holiday in the United States or any Calendar Day on which the commercial banks in the City of New York are required by law or other

governmental action to close, provided that the commercial banks in the City of New York shall not be deemed to be required to be closed

due to a “stay at home,” “shelter in place,” “non-essential employee” or similar orders or restrictions

or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer

systems (including for wire transfers) of commercial banks in the City of New York generally are open for use by customers on such Calendar

Day.

1.6.

“Calendar Day” means each and every day of the week (Sunday, Monday, Tuesday, Wednesday, Thursday, Friday and

Saturday).

1.7.

“Commission” means the United States Securities and Exchange Commission.

1.8.

“Common Stock” means the Class A common stock of the Company, $0.0001 par value per share, and any other class

of securities into which such securities may hereafter be reclassified or changed.

1.9.

“Common Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the

holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant

or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof

to receive, Common Stock.

1.10.

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated

thereunder.

1.11.

“Exchange Cap” means, unless and until Stockholder Approval is obtained, a number of shares of Common Stock

equal to nineteen and ninety-nine hundredths percent (19.99%) of the shares of Common Stock issued and outstanding immediately prior

to the execution of the Securities Purchase Agreement (subject to equitable adjustment for any stock split, stock dividend, stock combination,

recapitalization or similar transaction affecting the Common Stock after the date hereof), reduced by the aggregate number of shares

of Common Stock issued or issuable pursuant to the other Transaction Documents.

1.12.

“Exempt Issuance” means (i) any conventional bank loans that are not convertible into, or exercisable or exchangeable

for, shares of Common Stock or Common Stock Equivalents and do not involve any issuance of any shares of Common Stock or Common Stock

Equivalents or other security of the Company in connection therewith; (ii) shares of Common Stock or options issued to employees, officers

or directors of the Company pursuant to the Company’s equity incentive plans or pursuant to the compensation agreements previously

authorized by the Board of Directors; (iii) securities issued upon the exercise or exchange of or conversion of any Securities issued

hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on

the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number

of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection

with stock splits or combinations) or to extend the term of such securities; and (iv) securities issued pursuant to acquisitions or strategic

transactions (whether by merger, consolidation, purchase of equity, purchase of assets, reorganization or otherwise) approved by a majority

of the disinterested directors of the Company, provided that such securities are issued as “restricted securities” (as defined

in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith

during the one hundred eighty (180) days following the Release Date, and provided that any such issuance shall only be to a Person (or

to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business

synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds,

but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an

entity whose primary business is investing in securities.

1.13.

“Note” means the Convertible Promissory Note issued by the Company to the initial Holder pursuant to the Securities

Purchase Agreement, as the same may be amended, restated, or otherwise modified from time to time.

1.14.

“Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association,

joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any

kind.

1.15.

“Release Date” means the later of (x) the earlier of (i) the Resale Effective Date or (ii) the date that the

Securities can be sold, assigned or transferred without restriction or limitation pursuant to Rule 144 or Rule 144A promulgated under

the Securities Act (or a successor rule thereto) or (y) the Stockholder Approval Notice Time.

1.16.

“Resale Effective Date” means the earliest of the date that (a) one or more Resale Registration Statements

registering for resale all Warrant Shares have been declared effective by the Commission, (b) all of the Warrant Shares have been sold

pursuant to Rule 144 or may be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, (c) following the one year anniversary

of the Closing Date provided that the applicable holder of Warrant Shares is not an Affiliate of the Company, or (d) all of the Warrant

Shares may be sold pursuant to an exemption from registration under Section 4(a)(1) of the Securities Act without volume or manner-of-sale

restrictions and Hunter Taubman Fischer & Li LLC has delivered to such holders a standing written unqualified opinion that resales

may then be made by such holders of the Warrant Shares pursuant to such exemption which opinion shall be in form and substance reasonably

acceptable to such holders.

1.17.

“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

1.18.

“Stockholder Approval” means such approval as may be required by the applicable rules and regulations of The

Nasdaq Stock Market LLC (or any successor entity) from the stockholders of the Company, or board of directors in lieu thereof, with respect

to issuance of all of the Warrants and the Warrant Shares upon the exercise thereof, including without limitation:

1.18.1.

to issue in excess of twenty percent (20%) of the outstanding shares of Common Stock at a deemed discount to the Nasdaq Minimum Price

(as defined in Nasdaq Listing Rule 5635(d)(1)(A)) immediately prior to execution of the Securities Purchase Agreement.

1.18.2.

to consent to the voluntary adjustment, from time to time, of the exercise price of any and all currently outstanding warrants pursuant

to Section 3.8.

1.18.3.

to permit the issuance of shares of Common Stock under this Warrant and the other Transaction Documents in excess of the Exchange Cap.

1.19.

“Stockholder Approval Notice Time” means the time of public availability of the Current Report on Form 8-K

filed by the Company with the Securities and Exchange Commission giving public notice of Stockholder Approval.

1.20.

“Subsidiary” means any subsidiary of the Company and shall, where applicable, also include any direct or indirect

subsidiary of the Company formed or acquired after the date hereof.

1.21.

“Trading Day” means a Calendar Day on which the principal Trading Market is open for trading.

1.22.

“Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted

for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select

Market, the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).

1.23.

“Transaction Documents” means the Securities Purchase Agreement dated September 4, 2026, these Warrants, such

other Warrants as contemplated in the Securities Purchase Agreement, the Placement Agent Agreement, the Lock-Up Agreement and all exhibits

and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.

1.24.

“Transfer Agent” means Continental Stock Transfer & Trust Company, the current transfer agent of the Company,

with a mailing address of 1 State Street, 30th Floor, New York, NY 10004-1561 and an email address of cstmail@continentalstock.com, and

any successor transfer agent of the Company.

1.25.

“VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if

the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date

(or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P.

(based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading

Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable,

(c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported

on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price

per share of Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an

independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably

acceptable to the Company, the fees and expenses of which shall be paid by the Company.

1.26.

“Warrants” means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the

Securities Purchase Agreement.

2. Exercise.

2.1.

Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any

time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed

PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise substantially in the form attached hereto as Exhibit

2.1 (the “Notice of Exercise”). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading

Days comprising the Standard Settlement Period (as defined in Section 2.6.1 herein) following the date of exercise as aforesaid, the

Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer

or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2.3 below is specified

in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other

type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder

shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available

hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation

within three (3) Trading Days after the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of

this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering

the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased.

The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The

Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day after receipt of such notice. The Holder

and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following

the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given

time may be less than the amount stated on the face hereof.

2.2.

Exercise Price. The exercise price per Warrant Share shall be $2.75, subject to adjustment hereunder (the “Exercise

Price”).

2.3.

Cashless Exercise. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus

contained therein is not available for the issuance of the Warrant Shares to the Holder or the resale of the Warrant Shares by the Holder,

then this Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the

Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

(A)

applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise

is (1) delivered pursuant to Section 2.1 hereof on a Calendar Day that is not a Trading Day or (2) delivered pursuant to Section 2.1

hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b) of Regulation NMS promulgated

under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately

preceding the date of the applicable Notice of Exercise or (z) the highest Bid Price of the Common Stock on the principal Trading Market

as reported by Bloomberg L.P. within two (2) hours of the Holder’s delivery of the Notice of Exercise pursuant to Section 2.1

hereof if such Notice of Exercise is delivered during “regular trading hours,” or within two (2) hours after the close

of “regular trading hours” on a Trading Day or (iii) the VWAP on the date of the applicable Notice of Exercise if the date

of such Notice of Exercise is a Trading Day and such Notice of Exercise is delivered pursuant to Section 2.1 hereof two (2) or more

hours following the close of “regular trading hours” on such Trading Day;

(B)

the

Exercise Price of this Warrant, as adjusted hereunder; and

(X)

the

number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such

exercise were by means of a cash exercise rather than a cashless exercise.

2.4.

Automatic Cashless Exercise on Termination Date. Notwithstanding anything herein to the contrary, on the Termination Date,

this Warrant shall be automatically exercised via cashless exercise pursuant to Section 2.3. If such automatic exercise would result

in the Holder exceeding the Beneficial Ownership Limitation, as defined in Section

2.7

hereof, then the Company shall hold in abeyance delivery of any Warrant Shares in excess of such Beneficial Ownership Limitation until

such time as the Holder notifies the Company that delivery of such Warrant Shares would not exceed the Beneficial Ownership Limitation.

2.5.

Holding Period for Cashless Exercise. If Warrant Shares are issued in a cashless exercise, the parties acknowledge and

agree that in accordance with Section 3(a)(9) of the Securities Act, the holding period of the Warrant Shares being issued may be tacked

on to the holding period of this Warrant. Without limiting any other provision in the Transaction Documents, assuming (i) the Holder

is not an Affiliate of the Company, and (ii) all of the applicable conditions of Rule 144 promulgated under the Securities Act with respect

to Holder and the Warrant Shares are met in the case of such a cashless exercise, the Company agrees that the Company will cause the

removal of the legend from such Warrant Shares (including by delivering an opinion of Hunter Taubman Fischer & Li LLC to the Company’s

transfer agent at its own expense to ensure the foregoing), and the Company agrees that the Holder is under no obligation to sell the

Warrant Shares issuable upon the exercise of the Warrant prior to removing the legend. The Company agrees not to take any position contrary

to this Section 2.5.

2.6.

Mechanics of Exercise.

2.6.1.

Delivery of Warrant Shares upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted

by the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository

Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant

in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale

of the Warrant Shares by Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations

pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate or by electronic

delivery (at the election of the Holder), for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise

to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after the

delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement Period after

the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”). Upon

delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the

Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided

that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) one

(1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise.

Notwithstanding anything herein to the contrary, upon delivery of the Notice of Exercise, the Holder shall immediately be deemed for

purposes of Regulation SHO under the Exchange Act to have become the holder of the Warrant Shares irrespective of the date of delivery

of the Warrant Shares. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise

by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each

$1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise),

$10 per Trading Day (increasing to $20 per Trading Day on the third (3rd) Trading Day after the Warrant Share Delivery Date) for each

Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company

agrees to maintain a Transfer Agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable.

As used herein, “Standard Settlement Period” means the standard settlement period, expressed in a number of

Trading Days, on the Company’s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of

the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m.

(New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Securities Purchase

Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial

Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of

the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.

2.6.2.

Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request

of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new

Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant

shall in all other respects be identical with this Warrant.

2.6.3.

Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant

to Section 2.6.1 by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

2.6.4.

Compensation for Buy-In on Failure to Timely Deliver Warrant Shares upon Exercise. In addition to any other rights available

to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions

of Section 2.6.1 above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required

by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares

of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon

such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which

(x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds

(y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection

with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B)

at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise

was not honored and return any amount received by the Company in respect of the Exercise Price for those Warrant Shares (in which case

such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had

the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having

a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate

sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall

be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder

in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s

right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific

performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise

of the Warrant as required pursuant to the terms hereof.

2.6.5.

No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise

of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company

shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied

by the Exercise Price or round up to the next whole share.

2.6.6.

Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer

tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the

Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;

provided, however, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder,

this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto as Exhibit 2.6.6 duly executed

by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax

incidental thereto. The Company shall pay all Transfer Agent fees required for same- Trading Day processing of any Notice of Exercise

and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for

same-Trading Day electronic delivery of the Warrant Shares.

2.6.7.

Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise

of this Warrant, pursuant to the terms hereof.

2.7.

Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not

have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to

such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates,

and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution

Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of

the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties

shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is

being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, unexercised

portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion

of the unexercised or unconverted portion of any other securities of the Company (including, without limitation, any other Common Stock

Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the

Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2.7,

beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated

thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance

with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.

To the extent that the limitation contained in this Section 2.7 applies, the determination of whether this Warrant is exercisable (in

relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant

is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s

determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates

and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,

and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to

any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations

promulgated thereunder. For purposes of this Section 2.7, in determining the number of outstanding shares of Common Stock, a Holder may

rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report

filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice

by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request

of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common

Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the

conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since

the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation”

shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of Common Stock outstanding

immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice

to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2.7, provided that the Beneficial

Ownership Limitation in no event exceeds 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to

the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2.7 shall

continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until sixty-one (61) Calendar Days after

such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than

in strict conformity with the terms of this Section 2.7 to correct this paragraph (or any portion hereof) which may be defective or inconsistent

with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly

give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

2.8.

Exchange Cap. Notwithstanding anything to the contrary contained in this Warrant, unless and until Stockholder Approval

is obtained, the Company shall not issue any shares of Common Stock upon exercise of this Warrant to the extent that such issuance, when

aggregated with all other shares of Common Stock issued or issuable pursuant to the Transaction Documents, would exceed the Exchange

Cap. Any portion of this Warrant that is not exercisable as a result of the operation of this Section shall remain outstanding and shall

become exercisable at such time, if ever, as such exercise would no longer cause the Exchange Cap to be exceeded, or upon Stockholder

Approval being obtained, whichever occurs first.

3. Certain

Adjustments.

3.1.

Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or

otherwise makes a distribution or distributions on shares of Common Stock or any other equity or equity equivalent securities payable

in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise

of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way

of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares

of Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of

which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before

such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the

number of Shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this

Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3.1 shall become effective immediately after the record

date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after

the effective date in the case of a subdivision, combination or re-classification.

3.2.

Subsequent Equity Sales. If, at any time from and after the occurrence of the Anti- Dilution Trigger Event and continuing

thereafter until the Termination Date (such period, the “Subsequent Issuance Adjustment Period”), the Company

issues, sells, enters into an agreement to sell, or grants any option to purchase, or sells, enters into an agreement to sell, or grants

any right to reprice, or otherwise disposes of or issues (or announces any offer, sale, grant or any option to purchase or other disposition),

or, in accordance with this Section 3.2, is deemed to have issued or sold, any shares of Common Stock or Common Stock Equivalents for

a consideration per share less than a price equal to the Exercise Price in effect immediately prior to such issue or sale or deemed issuance

or sale (such Exercise Price then in effect is referred to as the “Applicable Price”) (the foregoing a “Dilutive

Issuance”), then simultaneously with the consummation (or, if earlier, the announcement) of such Dilutive Issuance, the

Exercise Price then in effect shall be reduced to an amount equal to the lower of (a) the Dilutive Issuance price or (b) the lowest VWAP

during the five (5) consecutive Trading Days immediately following the Dilutive Issuance (such lower price, the “Base Share

Price”). Notwithstanding the foregoing, no adjustments shall be made, paid or issued under this Section 3.2 in respect

of an Exempt Issuance. For the avoidance of doubt, in the event the Exercise Price has been adjusted pursuant to this Section 3.2 and

the Dilutive Issuance that triggered such adjustment does not occur, is not consummated, is unwound or is cancelled after the facts for

any reason whatsoever, in no event shall the Exercise Price be readjusted to the Exercise Price that would have been in effect if such

Dilutive Issuance had not occurred or been consummated. For all purposes of the foregoing, the following shall be applicable:

3.2.1.

Issuance of Options. If, during the Subsequent Issuance Adjustment Period, the Company in any manner grants or sells any

Options and the lowest price per share for which one share of Common Stock is issuable upon the exercise of any such Option or upon conversion,

exercise or exchange of any convertible securities (“Convertible Securities”) issuable upon exercise of any

such Option (such shares of Common Stock issuable upon such exercise of any Option or upon conversion, exercise or exchange of any Convertible

Securities, the “Convertible Securities Shares”) is less than the Applicable Price, then such shares of Common

Stock shall be deemed to be outstanding and to have been issued and sold by the Company at the time of the granting or sale of such Option

for such price per share. For purposes of this Section 3.2.1, the “lowest price per share for which one share of Common Stock is

issuable upon the exercise of any such Option or upon conversion, exercise or exchange of any Convertible Securities issuable upon exercise

of any such Option” shall be equal to (A) the sum of (1) the lowest amount of consideration (if any) received or receivable by

the Company with respect to any one Convertible Securities Share upon the granting or sale of such Option, upon exercise of such Option

and upon conversion, exercise or exchange of any Convertible Security issuable upon exercise of such Option and (2) the lowest exercise

price set forth in such Option for which one Convertible Securities Share is issuable upon the exercise of any such Option or upon conversion,

exercise or exchange of any Convertible Securities issuable upon exercise of any such Option, minus (B) the sum of all amounts paid or

payable to the holder of such Option (or any other Person), with respect to any one Convertible Securities Share, upon the granting or

sale of such Option, upon exercise of such Option and upon conversion, exercise or exchange of any Convertible Security issuable upon

exercise of such Option plus the value of any other consideration received or receivable by, or benefit conferred on, the holder of such

Option (or any other Person), with respect to any one Convertible Securities Share. Except as contemplated below, no further adjustment

of the Exercise Price shall be made upon the actual issuance of such Convertible Securities Share or of such Convertible Securities upon

the exercise of such Options or upon the actual issuance of such Convertible Securities Share upon conversion, exercise or exchange of

such Convertible Securities.

3.2.2.

Issuance of Convertible Securities. If, during the Subsequent Issuance Adjustment Period , the Company in any manner issues

or sells any Convertible Securities and the lowest price per share for which one Convertible Securities Share is issuable upon the conversion,

exercise or exchange thereof is less than the Applicable Price, then such Convertible Securities Share shall be deemed to be outstanding

and to have been issued and sold by the Company at the time of the issuance or sale of such Convertible Securities for such price per

share. For the purposes of this Section 3.2.2, the “lowest price per share for which one Convertible Securities Share is issuable

upon the conversion, exercise or exchange thereof” shall be equal to (A) the sum of (1) the lowest amount of consideration (if

any) received or receivable by the Company with respect to one Convertible Securities Share upon the issuance or sale of the Convertible

Security and upon conversion, exercise or exchange of such Convertible Security and (2) the lowest conversion price set forth in such

Convertible Security for which one Convertible Securities Share is issuable upon conversion, exercise or exchange thereof, minus (B)

the sum of all amounts paid or payable to the holder of such Convertible Security (or any other Person), with respect to any one Convertible

Securities Share, upon the issuance or sale of such Convertible Security plus the value of any other consideration received or receivable

by, or benefit conferred on, the holder of such Convertible Security (or any other Person), with respect to any one Convertible Securities

Share. Except as contemplated below, no further adjustment of the Exercise Price shall be made upon the actual issuance of such Convertible

Securities Share upon conversion, exercise or exchange of such Convertible Securities, and if any such issue or sale of such Convertible

Securities is made upon exercise of any Options for which adjustment of the Exercise Price has been or is to be made pursuant to other

provisions of this Section 3.2, except as contemplated below, no further adjustment of the Exercise Price shall be made by reason of

such issue or sale.

3.2.3.

Change in Option Price or Rate of Conversion. If, during the Subsequent Issuance Adjustment Period , the purchase or exercise

price provided for in any Options, the additional consideration, if any, payable upon the issue, conversion, exercise or exchange of

any Convertible Securities, or the rate at which any Convertible Securities are convertible into or exercisable or exchangeable for shares

of Common Stock increases or decreases at any time (other than proportional changes in conversion or exercise prices, as applicable,

in connection with an event referred to in Section 3.1), the Exercise Price in effect at the time of such increase or decrease shall

be adjusted to the Exercise Price which would have been in effect at such time had such Options or Convertible Securities provided for

such increased or decreased purchase price, additional consideration or increased or decreased conversion rate, as the case may be, at

the time initially granted, issued or sold. For purposes of this Section 3.2.3, if the terms of any Option or Convertible Security that

was outstanding as of the date of issuance of this Warrant are increased or decreased in the manner described in the immediately preceding

sentence, then such Option or Convertible Security and the Convertible Securities Share deemed issuable upon exercise, conversion or

exchange thereof shall be deemed to have been issued as of the date of such increase or decrease. No adjustment pursuant to this Section

3.2 shall be made if such adjustment would result in an increase of the Exercise Price then in effect.

3.2.4.

Calculation of Consideration Received. If any Option or Convertible Security is issued in connection with the issuance

or sale or deemed issuance or sale of any other securities of the Company (the “Primary Security”, and such

Option or Convertible Security, the “Secondary Securities” and together with the Primary Security, each a “Unit”),

together comprising one integrated transaction, the aggregate consideration per share with respect to such Primary Security shall be

deemed to be the lowest of (x) the purchase price of such Unit, (y) if such Primary Security is an Option and/or Convertible Security,

the lowest price per share for which one share of Common Stock is at any time issuable upon the exercise or conversion of the Primary

Security in accordance with Section 3.2.1 or 3.2.2 above and (z) the lowest VWAP of the shares of Common Stock on any Trading Day during

the five (5) consecutive Trading Days immediately following the public announcement of such Dilutive Issuance (for the avoidance of doubt,

if such public announcement is released prior to the opening of the Principal Market on a Trading Day, such Trading Day shall be the

first Trading Day in such five (5) Trading Day period). If any shares of Common Stock, Options or Convertible Securities are issued or

sold or deemed to have been issued or sold for cash, the consideration received therefor will be deemed to be the net amount of cash

received by the Company therefor. If any shares of Common Stock, Options or Convertible Securities are issued or sold for a consideration

other than cash, the amount of such consideration received by the Company will be the fair value of such consideration, except where

such consideration consists of publicly traded securities, in which case the amount of consideration received by the Company for such

securities will be the arithmetic average of the VWAPs of such security for each of the five (5) Trading Days immediately preceding the

date of receipt. If any shares of Common Stock, Options or Convertible Securities are issued to the owners of the non-surviving entity

in connection with any merger in which the Company is the surviving entity, the amount of consideration therefor will be deemed to be

the fair market value of such portion of the net assets and business of the non-surviving entity as is attributable to such shares of

Common Stock, Options or Convertible Securities (as the case may be). The fair market value of any consideration other than cash or publicly

traded securities will be determined jointly by the Company and the Holder. If such parties are unable to reach agreement within ten

(10) Business Days after the occurrence of an event requiring valuation (the “Valuation Event”), the fair market

value of such consideration will be determined within five (5) Business Days after the tenth (10th) Business Day following such Valuation

Event by an independent, reputable appraiser jointly selected by the Company and the Holder. The determination of such appraiser shall

be final and binding upon all parties absent manifest error and the fees and expenses of such appraiser shall be borne by the Company.

3.2.5.

Record Date. If, during the Subsequent Issuance Adjustment Period , the Company takes a record of stockholders for the

purpose of entitling them (A) to receive a dividend or other distribution payable in shares of Common Stock, Options or in Convertible

Securities or (B) to subscribe for or purchase shares of Common Stock, Options or Convertible Securities, then such record date will

be deemed to be the date of the issue or sale of shares of Common Stock deemed to have been issued or sold upon the declaration of such

dividend or the making of such other distribution or the date of the granting of such right of subscription or purchase (as the case

may be).

3.3.

Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3.1 above, if at any time the Company grants,

issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to all (or

substantially all) of the record holders of any class of shares of Common Stock (the “Purchase Rights”), then

the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder

could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without

regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the

date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as

of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided,

however, that, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding

the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial

ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall

be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial

Ownership Limitation).

3.4.

Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend

or other distribution of its assets (or rights to acquire its assets) to all (or substantially all) holders of shares of Common Stock,

by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property

or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction)

(a “Distribution”), at any time after the issuance of this Warrant, then, in each such case, the Holder shall

be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had

held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise

hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for

such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined

for the participation in such Distribution (provided, however, that, to the extent that the Holder’s right to participate in any

such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to

participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution

to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever,

as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has

not been partially or completely exercised at the time of such Distribution, such portion of the Distribution shall be held in abeyance

for the benefit of the Holder until the Holder has exercised this Warrant.

3.5.

Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in

one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or

any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all

or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender

offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted

to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of

the outstanding Common Stock or 50% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly,

in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory

share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property,

or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other

business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with

another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock

or 50% or more of the voting power of the common equity of the Company (each a “Fundamental Transaction”),

then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have

been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without

regard to any limitation in Section 2.7 on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring

corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”)

receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is

exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2.7 on the exercise of this

Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such

Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental

Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the

relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the

securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate

Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary,

in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder’s option,

exercisable at any time concurrently with, or within 30 Trading Days after, the consummation of the Fundamental Transaction (or, if later,

the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the

Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on

the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is not within the

Company’s control, including not approved by the Company’s Board of Directors, the Holder shall only be entitled to receive

from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value

of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection

with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the

holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental

Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental

Transaction, such holders of Common Stock will be deemed to have received common stock/shares of the Successor Entity (which Entity may

be the Company following such Fundamental Transaction) in such Fundamental Transaction. “Black Scholes Value”

means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the “OV” function on Bloomberg,

L.P. (“Bloomberg”) determined as of the Trading Day of consummation of the applicable contemplated Fundamental

Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal

to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date,

(B) an expected volatility equal to the greater of (1) 100% and (2) the 100 day volatility as obtained from the HVT function on Bloomberg

(determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable

contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum

of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental

Transaction and (ii) the highest VWAP during the period beginning on the Trading Day immediately preceding the public announcement of

the applicable contemplated Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending

on the Trading Day of the Holder’s request pursuant to this Section 3.5 and (D) a remaining option time equal to the time between

the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E) a zero cost

of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration)

within the later of (i) five (5) Business Days after the Holder’s election and (ii) the date of consummation of the Fundamental

Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the

“Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant and the other

Transaction Documents in accordance with the provisions of this Section 3.5 pursuant to written agreements in form and substance reasonably

satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at

the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written

instrument substantially similar in form and substance to this Warrant that is exercisable for a corresponding number of shares of capital

stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise

of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an

exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value

of the shares of Common Stock prior to such Fundamental Transaction and the value of such shares of capital stock, such number of shares

of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to

the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the

occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term “Company” under this Warrant

(so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and

the other Transaction Documents referring to the “Company” shall refer instead to each of the Company and the Successor Entity

or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company,

may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the

obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company

and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt,

the Holder shall be entitled to the benefits of the provisions of this Section 3.5 regardless of (i) whether the Company has sufficient

authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the

Initial Exercise Date.

3.6.

Calculations. All calculations under this Section 3 shall be made to the nearest fraction of a cent as in the initial Exercise

Price or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed

to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares,

if any) issued and outstanding.

3.7.

Notice to Holder.

3.7.1.

Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the

Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting

adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

3.7.2.

Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever

form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock,

(C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares

of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with

any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any

sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into

other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding

up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email

address as it shall appear upon the Warrant Register of the Company, at least twenty (20) Calendar Days prior to the applicable record

or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend,

distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock

of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which

such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date

as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of Common Stock for

securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided

that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate

action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material,

non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission

pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the

date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

3.8.

Voluntary Adjustment by Company. Subject to the rules and regulations of the Trading Market and the consent of the Holder,

the Company may at any time during the term of this Warrant reduce the then current Exercise Price to any amount and for any period of

time deemed appropriate by the Board of Directors.

3.9.

Stockholder Approval. The Company shall hold a special meeting of stockholders (which may also be at the annual meeting

of stockholders; such meeting, the “Stockholder Approval Meeting”) at the earliest practicable date after the

date hereof, but in no event later than sixty (60) Calendar Days after the Closing Date for the purpose of obtaining Stockholder Approval,

if required to effect the purpose thereof, with the recommendation of the Board that such proposal be approved, and the Company shall

solicit proxies from its stockholders in connection therewith in the same manner as all other management proposals in such proxy statement

and all management-appointed proxyholders shall vote their proxies in favor of such proposal. The Company shall use its reasonable best

efforts to obtain such Stockholder Approval, and officers, directors, and shareholders subject to the Lock-Up Agreement shall cast their

proxies in favor of such proposal. The Stockholder Approval Meeting shall not be held between 9:30 a.m. (New York City time) and 4:02

p.m. (New York City time) on any Trading Day, and the Company shall file a Current Report on Form 8-K announcing the voting results of

the Stockholder Approval Meeting prior to 9:00 a.m. (New York City time) on the Trading Day immediately following the Stockholder Approval

Meeting (i.e., the same Trading Day if the Stockholder Approval Meeting is held prior to 9:30 a.m. (New York City time) on a Trading

Day). If the Company does not obtain Stockholder Approval at the first meeting, the Company shall call a meeting every sixty (60) days

thereafter to seek Stockholder Approval until the earlier of the date Stockholder Approval is obtained or these Warrants are no longer

outstanding.

4. Transfer

of Warrant.

4.1.

Transferability. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4.4

hereof, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or

in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment

of this Warrant substantially in the form attached hereto as Exhibit 2.6.6 duly executed by the Holder or its agent or attorney

and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment,

the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination

or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of

this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder

shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which

case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days after the date on which the Holder delivers

an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised

by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

4.2.

New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office

of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed

by the Holder or its agent or attorney. Subject to compliance with Section 4.1, as to any transfer which may be involved in such division

or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided

or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial Issuance Date of

this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

4.3.

Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose

(the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and

treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to

the Holder, and for all other purposes, absent actual notice to the contrary.

4.4.

Transfer Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant,

the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities

Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions,

the Company may require, as a condition of allowing such transfer, that (x) the transferor (other than in connection with a transfer

to an Affiliate of the transferor) provide to the Company an opinion of counsel to the effect that such transfer does not require registration

of such transferred Warrant under the Securities Act and (y) that the transferee agree in writing to be bound by the terms of the Securities

Purchase Agreement, with all the rights and obligations of a Purchaser under such agreements.

4.5.

Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant

and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to

or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities

law, except pursuant to sales registered or exempted under the Securities Act.

5. Miscellaneous.

5.1.

No Rights as Stockholder until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting

rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2.6.1, except

as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a “cashless exercise”

pursuant to Section 2.3 or to receive cash payments pursuant to Section 2.6.1 and Section 2.6.4 herein, in no event shall the Company

be required to net cash settle an exercise of this Warrant.

5.2.

Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably

satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,

and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,

shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the

Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant

or stock certificate.

5.3.

Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right

required or granted herein shall not be a Trading Day, then such action may be taken, or such right may be exercised, on the next succeeding

Trading Day.

5.4.

Authorized Shares.

5.4.1.

Reservation of Authorized and Unissued Shares. The Company covenants that, while the Warrant is outstanding, it will reserve

from its authorized and unissued Common Stock a sufficient number of shares of Common Stock to provide for the issuance of the Warrant

Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall

constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of

the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant

Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading

Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise

of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment

for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable (which means that no

further sums are required to be paid by the holders thereof in connection with the issue thereof) and free from all taxes, liens and

charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously

with such issue). If the Company does not have a sufficient number of authorized and unissued shares of Common Stock available to honor

the exercise of Warrants, the Company shall allocate the available number of Warrant Shares on a pro rata basis among all Holders exercising

Warrants, until such time as the Company has a sufficient number of authorized Common Stock to issue all Warrant Shares in full.

5.4.2.

Noncircumvention. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action,

including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation,

merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance

of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking

of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.

Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount

payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or

appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of

this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public

regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

5.4.3.

Authorizations, Exemptions and Consents. Before taking any action that would result in an adjustment in the number of Warrant

Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions

thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

5.5.

Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall

be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles

of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of

the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers,

stockholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City

of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City

of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated

hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that

it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient

venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any

such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)

to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient

service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any

other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,

the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys’

fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. Notwithstanding

the foregoing, nothing in this paragraph shall limit or restrict the federal district court in which a Holder may bring a claim under

the federal securities laws.

5.6.

Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,

and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

5.7.

Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder

shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies, notwithstanding the fact

that the right to exercise this Warrant terminates on the Termination Date. No provision of this Warrant shall be construed as a waiver

by the Holder of any rights which the Holder may have under the federal securities laws and the rules and regulations of the Commission

thereunder. Without limiting any other provision of this Warrant or the Securities Purchase Agreement, if the Company willfully and knowingly

fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the

Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’

fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise

enforcing any of its rights, powers or remedies hereunder.

5.8.

Notices. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without

limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight

courier service, addressed to the Company, at 435 Ericksen Ave NE, Suite 250, Bainbridge Island, WA 98110, United States, Attention:

Joseph Davy, Chief Executive Officer, email address: joe@banzai.io, or such other email address or address as the Company may specify

for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder

shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each

Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries

hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered

via e-mail at the e-mail address set forth in this Section 5.8 prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading

Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section

5.8 on a Calendar Day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading

Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the

party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material,

non- public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission

pursuant to a Current Report on Form 8-K.

5.9.

Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant

to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of

the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company

or by creditors of the Company.

5.10.

Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,

will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate

compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to

assert the defense in any action for specific performance that a remedy at law would be adequate.

5.11.

Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby

shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted

assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant

and shall be enforceable by the Holder or holder of Warrant Shares.

5.12.

Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company,

on the one hand, and a majority-in- interest of Holders of the Warrants, on the other hand. No modification or amendment of the provisions

hereof may be waived in a manner that is more favorable to other holder(s) of Warrants, as applicable, or to treat any holder(s) of Warrants

in a manner that is in any respect not equal to the treatment of all other holder(s) of Warrants.

5.13.

Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective

and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision

shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining

provisions of this Warrant.

5.14.

Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be

deemed a part of this Warrant.

********************

[PARA

Investor PIPE Common Warrant Signature Page Follows]

[PARA

Investor PIPE Common Warrant Signature Page]

WITNESS WHEREOF, the Company has caused this PIPE Common Warrant to be executed by its officer thereunto duly authorized as of the date

first above indicated.

BANZAI

INTERNATIONAL, INC.

By:

Name:

Joseph

Davy

Its:

Chief

Executive Officer

Exhibit

2.1

NOTICE

OF EXERCISE

TO:

BANZAI

INTERNATIONAL, INC.

(1)

The undersigned hereby elects to purchase Warrant Shares of the Company pursuant to the terms of the attached Warrant (only

if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

(2)

Payment shall take the form of (check applicable box):

[ ]

lawful money of the United States.

[ ]

permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in Section 2.3,

to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure

set forth in Section 2.3.

(3)

Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

____________________________________

The

Warrant Shares shall be delivered to the following DWAC Account Number:

____________________________________

(4)

The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

[PARA

Investor PIPE Common Warrant Exercise Notice – Investor Signature Page]

Name

of Investing Entity:

Signature

of Authorized Signatory of Investing Entity:

Name

of Authorized Signatory:

Title

of Authorized Signatory:

Date:

Exhibit

2.6.6

ASSIGNMENT

FORM

(To

assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase

shares of Common Stock.)

FOR

VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

Name:

Address:

Phone

Number:

Address:

Date:

Holder’s

Signature:

Holder’s

Address:

EX-10.1

Filename: ex10-1.htm · Sequence: 4

Exhibit

10.1

SECURITIES

PURCHASE AGREEMENT

This

Securities Purchase Agreement (this “Agreement”) is dated as of September 4, 2026, between Banzai International,

Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (including

their respective successors and assigns, each a “Purchaser” and collectively, the “Purchasers”).

WHEREAS,

subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended

(the “Securities Act”), and Rule 506 promulgated thereunder, the Company desires to issue and sell to each

Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully

described in this Agreement.

NOW,

THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the

receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

Definitions.

In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings

set forth in this Section 1:

1.1.

“Acquiring Person” shall have the meaning ascribed to such term in Section 4.5.

1.2.

“Action” shall have the meaning ascribed to such term in Section 3.2.4.

1.3.

“Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is

controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

1.4.

“Agreement” shall have the meaning ascribed to such term in the preamble.

1.5.

“BHCA” shall have the meaning ascribed to such term in Section 3.2.36.

1.6.

“Board of Directors” means the board of directors of the Company.

1.7.

“Business Day” means a Calendar Day other than a Saturday, Sunday or any other Calendar Day which is a federal

legal holiday in the United States or any Calendar Day on which the commercial banks in the City of New York are required by law or other

governmental action to close, provided that the commercial banks in the City of New York shall not be deemed to be required to be closed

due to a “stay at home,” “shelter in place,” “non-essential employee” or similar orders or restrictions

or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer

systems (including for wire transfers) of commercial banks in the City of New York generally are open for use by customers on such Calendar

Day.

1.8.

“Buy-In Price” shall have the meaning ascribed to such term in Section 4.1.4.

1.9.

“Calendar Day” means each and every day of the week (Sunday, Monday, Tuesday, Wednesday, Thursday, Friday and

Saturday).

1.10.

“Closing” means the closing of the purchase and sale of the Securities pursuant to Section 2.1.

1.11.

“Closing Date” means the Trading Day on which all of the Transaction Documents have been executed and delivered

by the applicable parties thereto, and all conditions precedent to (i) the Purchasers’ obligations to pay the Subscription Amount

and (ii) the Company’s obligations to deliver the Securities, in each case, have been satisfied or waived.

1.12.

“Code” means the Internal Revenue Code of 1986, as amended.

1.13.

“Commission” means the United States Securities and Exchange Commission.

1.14.

“Common Stock” means the common stock of the Company, $0.0001 par value per share, and any other class of securities

into which such securities may hereafter be reclassified or changed.

1.15.

“Common Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the

holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant

or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof

to receive, Common Stock.

1.16.

“Common Warrants” means the warrants to purchase shares of Common Stock delivered to the Purchasers at the

Closing in accordance with Section 2.1 hereof, which Common Warrants shall be in the form of Exhibit 1.16.1 attached

hereto.

1.17.

“Company” shall have the meaning ascribed to such term in the preamble.

1.18.

“Company Counsel” means with respect to U.S. federal securities law and New York law, Hunter Taubman Fischer

& Li LLC, 950 Third Avenue, 19th Floor, New York, NY 10022.

1.19.

“Disclosure Schedules” means the Disclosure Schedules of the Company delivered concurrently herewith.

1.20.

“Disclosure Time” means, (i) if this Agreement is signed on a Calendar Day that is not a Trading Day or after

9:00 a.m. (New York City time) and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading

Day immediately following the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this

Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m.

(New York City time) on the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent.

1.21.

“Disqualification Event” shall have the meaning ascribed to such term in Section 3.2.38.

1.22.

“Evaluation Date” shall have the meaning ascribed to such term in Section 3.2.13.

1.23.

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated

thereunder.

1.24.

“Exchange Cap” means, unless and until Stockholder Approval is obtained, a number of shares of Common Stock

equal to nineteen and ninety-nine hundredths percent (19.99%) of the shares of Common Stock issued and outstanding immediately prior

to the execution of this Agreement (subject to equitable adjustment for any stock split, stock dividend, stock combination, recapitalization

or similar transaction affecting the Common Stock after the date hereof), reduced by the aggregate number of shares of Common Stock issued

or issuable pursuant to the other Transaction Documents.

1.25.

“FCPA” means the Foreign Corrupt Practices Act of 1977, as amended.

1.26.

“Federal Reserve” shall have the meaning ascribed to such term in Section 3.2.36.

1.27.

“GAAP” shall have the meaning ascribed to such term in Section 3.2.2.

1.28.

“Indebtedness” shall have the meaning ascribed to such term in Section 3.2.22.

1.29.

“Intellectual Property Rights” shall have the meaning ascribed to such term in Section 3.2.10.

1.30.

“Issuer Covered Person” shall have the meaning ascribed to such term in Section 3.2.38.

1.31.

“IT Systems and Data” shall have the meaning ascribed to such term in Section 3.2.41.

1.32.

“Legend Removal Date” shall have the meaning ascribed to such term in Section 4.1.3.

1.33.

“Liens” means a lien, charge pledge, security interest, encumbrance, right of first refusal, preemptive right

or other restriction.

1.34.

“Lock-Up Agreement” means each Lock-Up Agreement, dated as of the date hereof, by and between the Company and

each of the directors, executive officers, employees and stockholders holding at least 10 percent (10%) of the outstanding shares of

Common Stock, in the form of Exhibit 1.34 attached hereto.

1.35.

“Material Adverse Effect” shall have the meaning assigned to such term in Section 3.1.2.

1.36.

“Material Permits” shall have the meaning ascribed to such term in Section 3.2.8.

1.37.

“Money Laundering Laws” shall have the meaning ascribed to such term in Section 3.2.37.

1.38.

“Note” means the Convertible Promissory Note issued by the Company to each Purchaser pursuant to Section 2.1,

in the form attached hereto as Exhibit 1.38, as the same may be amended, restated, or otherwise modified from time to time (including

pursuant to Section 2.1), and, where the context requires, collectively, the Notes issued to all of the Purchasers.

1.39.

“Note Shares” means all shares of Common Stock issuable upon conversion of the Note.

1.40.

“OFAC” shall have the meaning ascribed to such term in Section 3.2.34.

1.41.

“Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association,

joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any

kind.

1.42.

“Placement Agent” means Aegis Capital Corp.

1.43.

“Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an informal

investigation or partial proceeding, such as a deposition), whether commenced or threatened.

1.44.

“Public Information Failure” shall have the meaning ascribed to such term in Section 4.2.2.

1.45.

“Purchaser” shall have the meaning ascribed to such term in the preamble.

1.46.

“Purchaser Party” shall have the meaning ascribed to such term in Section 4.8.

1.47.

“Required Approvals” shall have the meaning ascribed to such term in Section 3.1.5.

1.48.

“Resale Effective Date” means the earliest of the date that (a) all of the Note Shares and Warrant Shares have

been sold pursuant to Rule 144 or may be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, (b) following the one

year anniversary of the Closing Date provided that the applicable holder of Note Shares or Warrant Shares is not an Affiliate of the

Company, or (c) all of the Note Shares and Warrant Shares may be sold pursuant to an exemption from registration under Section 4(a)(1)

of the Securities Act without volume or manner-of-sale restrictions and Company Counsel has delivered to such holders a written opinion

in customary form that resales may then be made by such holders of the Note Shares and Warrant Shares pursuant to such exemption which

opinion shall be in form and substance reasonably acceptable to such holders.

1.49.

“Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be

amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially

the same purpose and effect as such Rule.

1.50.

“Rule 424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be

amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially

the same purpose and effect as such Rule.

1.51.

“SEC Reports” shall have the meaning ascribed to such term in Section 3.2.2.

1.52.

“Securities” means the Note, the Note Shares, the Warrants and the Warrant Shares purchased or issued pursuant

to this Agreement.

1.53.

“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

1.54.

“Short Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange

Act (but shall not be deemed to include locating and/or borrowing shares of Common Stock).

1.55.

“Stockholder Approval” means such approval as may be required by the applicable rules and regulations of The

Nasdaq Stock Market LLC (or any successor entity) from the stockholders of the Company, or board of directors in lieu thereof, with respect

to:

1.55.1.

to issue in excess of twenty percent (20%) of the outstanding shares of Common Stock at a deemed discount to the Nasdaq Minimum Price

(as defined in Nasdaq Listing Rule 5635(d)(1)(A)) immediately prior to execution of this Agreement.

1.55.2.

to consent to the voluntary adjustment, from time to time, of the exercise price of any and all currently outstanding warrants in the

discretion of the Company’s Board of Directors.

1.55.3.

to permit the issuance of shares of Common Stock under the Note, the Warrants and the other Transaction Documents in excess of the Exchange

Cap.

1.56.

“Stockholder Approval Notice Time” means the time of public availability of the Current Report on Form 8-K

filed by the Company with the Securities and Exchange Commission giving public notice of Stockholder Approval.

1.57.

“Subscription Amount” means, as to each Purchaser, the aggregate amount to be paid for the Securities purchased

hereunder as specified below such Purchaser’s name on the signature page of this Agreement and next to the heading “Subscription

Amount,” in United States dollars and in immediately available funds.

1.58.

“Subsidiary” means any subsidiary of the Company as set forth in Schedule 3.1.1 and shall, where applicable,

also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.

1.59.

“Trading Day” means a Calendar Day on which the principal Trading Market is open for trading.

1.60.

“Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted

for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select

Market, the New York Stock Exchange, the OTCQB, OTCQX, Pink Open Market (or any successors to any of the foregoing).

1.61.

“Transaction Documents” means this Agreement, the Note, the Warrants, the Lock-Up Agreement and all exhibits

and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.

1.62.

“Transfer Agent” means Continental Stock Transfer & Trust Company, the current transfer agent of the Company,

with a mailing address of 1 State Street, 30th Floor, New York, NY 10004-1561 and an email address of cstmail@continentalstock.com, and

any successor transfer agent of the Company.

1.63.

“VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if

the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date

(or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P.

(based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading

Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable,

(c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported

on the OTC Pink (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per

share of Common Stock so reported, or (d) in all other cases, the fair market value of the Common Stock as determined by an independent

appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable

to the Company, the fees and expenses of which shall be paid by the Company.

1.64.

“Warrants” means the Common Warrants.

1.65.

“Warrant Shares” means the shares of Common Stock underlying the Warrants.

Purchase and Sale.

2.1.

Closing. On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with

the execution and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not

jointly, agree to purchase, a Note in the initial aggregate principal amount of $2,142,857.14, subject to increase up to an aggregate

principal amount of $3,571,428.57 in accordance with Section 2.3, and a Warrant to purchase up to an aggregate of 779,221 shares of Common

Stock, subject to the issuance of additional Warrants in accordance with Section 2.3.

At the Closing, the Company shall deliver to each Purchaser its respective Note and Warrant, and the Company and each Purchaser shall

deliver the other items set forth in Sections 2.4 and 2.5 deliverable at the Closing. Upon satisfaction of the covenants and conditions

set forth in Section 2.6, the Closing shall occur remotely by electronic transfer of the Closing documentation or at such location as

the parties shall mutually agree. For the avoidance of doubt, the Closing is the closing of the execution and delivery of the Transaction

Documents and the issuance of the Note and the Warrant with respect to Tranche 1, and is separate from each subsequent Tranche Closing.

2.2.

Tranches. The Purchasers’ Subscription Amounts shall be payable in up to three installments (each, a “Tranche”)

as follows:

2.2.1.

Tranche 1: an amount equal to $1,500,000 (the “Initial Tranche Amount”), payable upon execution

and delivery of this Agreement (such funding, together with the Closing, the “Initial Closing”).

2.2.2.

Tranche 2: an amount equal to $500,000 (the “Tranche 2 Amount”), payable within three (3) Business

Days following the Company’s confidential submission to the Commission of a draft registration statement on Form S-1 (or any amendment

thereto) relating to a proposed underwritten public offering of Common Stock (such submission, the “Confidential Filing,”

and such funding, the “Tranche 2 Closing”).

2.2.3.

Tranche 3: an amount equal to $500,000 (the “Tranche 3 Amount”), payable within three (3) Business

Days following the public filing of such registration statement on Form S-1 (or any amendment thereto) with the Commission (such filing,

the “Public Filing,” and such funding, the “Tranche 3 Closing”; each of the Tranche

2 Closing and the Tranche 3 Closing, together with the Initial Closing, a “Tranche Closing”).

2.3.

Increase Upon Funding of Tranche 2 and Tranche 3. Upon the funding of Tranche 2 in accordance with Section 2.2, the outstanding

principal amount of each Purchaser’s Note shall automatically, and without any further action on the part of the Company or such

Purchaser, be increased by an amount equal to such Purchaser’s pro rata share of $714,285.71, and the Company shall issue to such

Purchaser an additional Warrant to purchase up to such Purchaser’s pro rata share of 259,740 shares of Common Stock. Upon the funding

of Tranche 3 in accordance with Section 2.2, the outstanding principal amount of each Purchaser’s Note shall automatically, and

without any further action on the part of the Company or such Purchaser, be increased by an amount equal to such Purchaser’s pro

rata share of $714,285.72, and the Company shall issue to such Purchaser an additional Warrant to purchase up to such Purchaser’s

pro rata share of 259,740 shares of Common Stock. Promptly following any such funding, the Company shall, at the Company’s sole

cost, execute and deliver to such Purchaser an amended and restated Note reflecting such increase and a Warrant certificate representing

such additional Warrant Shares; provided that the failure to deliver any such amended and restated Note or Warrant certificate shall

not affect the automatic increases described above.

2.4.

Deliveries.

2.4.1.

The Company shall deliver or cause to be delivered to each Purchaser or the Placement Agent, as appropriate, the following at the times

stated:

2.4.1.1

on the date hereof:

2.4.1.1.1.

this Agreement duly executed by the Company.

2.4.1.1.2.

a certificate executed by the Chief Financial Officer of the Company in customary form reasonably satisfactory to the Placement Agent

and its counsel.

2.4.1.1.3.

the Lock-Up Agreements.

2.4.1.2

on or prior to the Closing Date:

2.4.1.2.1.

a legal opinion of Company Counsel, addressed to the Placement Agent and the Purchasers, in form and substance reasonably acceptable

to the Placement Agent and the Purchasers.

2.4.1.2.2.

a copy of the irrevocable instructions to the Transfer Agent authorizing the reservation and issuance of the Note Shares and the Warrant

Shares in accordance with the Transaction Documents.

2.4.1.2.3.

the Company’s wire instructions, on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer.

2.4.1.2.4.

a duly executed and delivered Officers’ Certificate, in customary form reasonably satisfactory to the Placement Agent and its counsel.

2.4.1.2.5.

the PIPE Common Warrants registered in the name of such Purchaser, to purchase up to such Purchaser’s pro rata portion of 779,221

shares of Common Stock, with an exercise price equal to $2.75 per share, subject to adjustment as provided therein.

2.4.1.2.6.

the Note, registered in the name of such Purchaser, in the initial principal amount equal to such Purchaser’s pro rata portion

of $2,142,857.14, subject to adjustment as provided therein.

2.4.2.

Each Purchaser, and the Placement Agent, as applicable, shall deliver or cause to be delivered to the Company the following at the times

stated:

2.4.2.1

on the date hereof:

2.4.2.1.1.

this Agreement duly executed by such Purchaser.

2.4.2.2

on or prior to the Closing Date:

2.4.2.2.1.

such Purchaser’s Initial Tranche Amount by wire transfer of immediately available funds to the account specified in writing by

the Company.

2.5.

Funding of Subsequent Tranches. With respect to Tranche 2, the Company shall provide written notice to the Purchasers promptly

upon the Confidential Filing (a “Tranche 2 Notice”), and each Purchaser shall wire transfer its portion of

the Tranche 2 Amount to the account specified in writing by the Company no later than three (3) Business Days after receipt of the Tranche

2 Notice. With respect to Tranche 3, the Company shall provide written notice to the Purchasers promptly upon the Public Filing (a “Tranche

3 Notice”), and each Purchaser shall wire transfer its portion of the Tranche 3 Amount to the account specified in writing

by the Company no later than three (3) Business Days after receipt of the Tranche 3 Notice. Each Purchaser shall, upon the Company’s

reasonable request, deliver to the Company evidence reasonably satisfactory to the Company of such Purchaser’s financial capacity

to fund the remaining Tranches (such as a bank or brokerage statement or a proof-of-funds letter).

2.6.

Closing Conditions.

2.6.1.

The obligations of the Company hereunder in connection with the Closing are subject to each of the following conditions being met:

2.6.1.1

the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse

Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained herein (unless

as of a specific date therein in which case they shall be accurate as of such date).

2.6.1.2

all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been

performed.

2.6.1.3

the delivery by each Purchaser of the items set forth in Section 2.4.2 of this Agreement.

2.6.2.

The respective obligations of the Purchasers hereunder in connection with the Closing are subject to each of the following conditions

being met:

2.6.2.1

the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse

Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless

as of a specific date therein in which case they shall be accurate as of such date).

2.6.2.2

all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed.

2.6.2.3

the delivery by the Company of the items set forth in Section 2.4.1 of this Agreement.

2.6.2.4

there shall have been no Material Adverse Effect with respect to the Company since the date hereof.

2.6.2.5

from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company’s

principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall

not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such

service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities

nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such

magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of

such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.

2.6.3.

Additional Conditions to Tranche 2 and Tranche 3. Notwithstanding anything to the contrary in this Agreement, the obligation

of each Purchaser to fund the Tranche 2 Amount and the Tranche 3 Amount is further subject to the satisfaction (or waiver in writing

by such Purchaser) of each of the following, at or prior to the funding of the applicable Tranche: (i) the accuracy in all material respects

(or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) of the representations

and warranties of the Company contained herein as of the applicable funding date (unless as of a specific date therein, in which case

they shall be accurate as of such date), (ii) all obligations, covenants and agreements of the Company required to be performed at or

prior to the applicable funding date shall have been performed, (iii) no Material Adverse Effect shall have occurred and be continuing,

(iv) no Event of Default (as defined in the Note) shall have occurred and be continuing under the Note, and (v) with respect to Tranche

2, the Confidential Filing shall have occurred, and with respect to Tranche 3, the Public Filing shall have occurred.

Representations and

Warranties.

3.1.

Representations and Warranties of the Company. The Company hereby makes the following representations and warranties to

each Purchaser:

3.1.1.

Subsidiaries. All of the direct and indirect subsidiaries of the Company are set forth on Schedule 3.1.1. The Company owns,

directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of

the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free

of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to

the Subsidiaries or any of them in the Transaction Documents shall be disregarded.

3.1.2.

Organization and Qualification. Each of the Company and its operating Subsidiaries is an entity duly incorporated or otherwise

organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite

power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company

nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws

or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in

good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property

owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be,

could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any

Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial

or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company’s ability

to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a “Material

Adverse Effect”; provided, however, that “Material Adverse Effect” shall not include any event,

occurrence, fact, condition or change, directly or indirectly, arising out of or attributable to: (i) the announcement, pendency or completion

of the transactions contemplated by the Transaction Documents or (ii) any action required or permitted by the Transaction Documents or

any action taken (or omitted to be taken) with the written consent of or at the written request of Purchaser). As to all Company and

Subsidiary power, authority and qualification, no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing

or seeking to revoke, limit or curtail such power and authority or qualification.

3.1.3.

Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate

the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations

hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and

the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part

of the Company and no further action is required by the Company, the Board of Directors or the Company’s stockholders in connection

herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which

it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms

hereof and thereof, will constitute the legal, valid and binding obligation of the Company enforceable against the Company in accordance

with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium

and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to

the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution

provisions may be limited by applicable law.

3.1.4.

No Conflicts. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents

to which it is a party, the issuance and sale of the Securities and the

consummation by it of the transactions contemplated hereby and thereby do not and will not (i) conflict with or violate any provision

of the Company’s or any Subsidiary’s certificate or articles of incorporation, bylaws or other organizational or charter

documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default)

under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any

rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation (with or without notice, lapse of

time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or

other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary

is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation,

order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary

is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary

is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result

in a Material Adverse Effect.

3.1.5.

Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of,

give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority

or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i)

the filings required pursuant to Section 4.4 of this Agreement, (ii) the notice and/or application(s) to each applicable Trading Market

for the issuance and sale of the Securities and the listing of the Note Shares and Warrant Shares for trading thereon in the time and

manner required thereby, (iii) the filing of Form D with the Commission, (iv) the Stockholder Approval and such other filings as are

required to be made under applicable state securities laws (the “Required Approvals”).

3.2.

Issuance of the Securities. The Securities are duly authorized and, when issued and paid for in accordance with the applicable

Transaction Documents, will be duly and validly issued, fully paid and nonassessable (which means that no further sums are required to

be paid by the holders thereof in connection with the issue thereof), free and clear of all Liens imposed by the Company other than restrictions

on transfer provided for in the Transaction Documents and applicable law. The Note Shares and the Warrant Shares, when issued in accordance

with the terms of the Transaction Documents, will be validly issued, fully paid and nonassessable (which means that no further sums are

required to be paid by the holders thereof in connection with the issue thereof), free and clear of all Liens imposed by the Company

other than restrictions on transfer provided for in the Transaction Documents and applicable law. As of the date hereof, the Company

has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number

of shares of Common Stock for the purpose of enabling the Company to issue the maximum number of Note Shares issuable upon conversion

of the Note and the maximum number of Warrant Shares issuable upon exercise of the Warrants, without regard to any limitations upon conversion

of the Note or exercise of the Warrants and assuming conversion of the Note at the Conversion Price (as defined in the Note) and exercise

of the Warrants at the Exercise Price (as defined in the Warrants) (as adjusted for forward and reverse stock splits, recapitalizations,

stock dividends and the like after the date hereof).

3.2.1.

Capitalization. The capitalization of the Company as of the date hereof is as set forth on Schedule 3.2.1, which Schedule

3.2.1 shall also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the

date hereof. Other than as stated in Schedule 3.2.1, the Company has not issued any capital stock since its most recently filed periodic

report under the Exchange Act, other than pursuant to the exercise of employee stock options under the Company’s stock option plans,

the issuance of shares of Common Stock to employees pursuant to the Company’s employee stock purchase plans and pursuant to the

conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the

Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate

in the transactions contemplated by the Transaction Documents. Except as set forth in Schedule 3.2.1, or pursuant to this Agreement,

there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to,

or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe

for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements

by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents

or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue

shares of Common Stock or other securities to any Person (other than the Purchasers). Except as set forth in Schedule 3.2.1, there are

no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange

or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. Except as set forth in

Schedule 3.2.1, there are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar

provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may

become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or “phantom

stock” plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are

duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws,

and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.

No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the

Securities. There are no stockholders’ agreements, voting agreements or other similar agreements with respect to the Company’s

capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders.

3.2.2.

SEC Reports; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents

required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof,

for the two years preceding the date hereof (or such shorter period as the Company was

required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated

by reference therein, being collectively referred to herein as the “SEC Reports”) on a timely basis or has

received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As

of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange

Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a

material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under

which they were made, not misleading. The Company is not currently an issuer subject to Rule 144(i) under the Securities Act. The Company

has filed Form 10 information at least one year prior to the date hereof. The financial statements of the Company included in the SEC

Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with

respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally

accepted accounting principles applied on a consistent basis during the periods involved (“GAAP”), except as

may be otherwise specified in such financial statements or the notes thereto, and fairly present in all material respects the financial

position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows

for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.

3.2.3.

Material Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements

included within the SEC Reports, except as set forth on Schedule 3.2.3, (i) there has been no event, occurrence or development that has

had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent

or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice

and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP or disclosed in filings

made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend

or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any

shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant

to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment

of information. Except for the issuance of the Securities contemplated by this Agreement, no event, liability, fact, circumstance, occurrence

or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or

their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed

by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed

at least one (1) Trading Day prior to the date that this representation is made.

3.2.4. Litigation.

Except as set forth in Schedule 3.2.4, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending

or, to the knowledge of the Company, threatened against or affecting

the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative

agency or regulatory authority (federal, state, county, local or foreign) (collectively, an “Action”).

None of the Actions set forth on Schedule 3.2.4, (i) adversely affects or challenges the legality, validity or enforceability of any

of the Transaction Documents or (ii) would, if there were an unfavorable decision, have or reasonably be expected to result

in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the

subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of

fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by

the Commission involving the Company or any current or former director or officer of the Company, except in the ordinary course of

business that would not have a Material Adverse Effect. The Commission has not issued any stop order or other order suspending the

effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.

3.2.5.

Labor Relations. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees

of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its Subsidiaries’

employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary, and neither

the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe

that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary

is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary

information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third

party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability

with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local

and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,

except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse

Effect.

3.2.6.

Compliance. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred

that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under),

nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,

loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound

(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree, or order of any court, arbitrator

or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental

authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational

health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be

expected to result in a Material Adverse Effect.

3.2.7.

Environmental Laws. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws

relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface

or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants,

or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into the environment, or otherwise

relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials,

as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters,

orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (“Environmental Laws”);

(ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective

businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i),

(ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.

3.2.8.

Regulatory Permits. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the

appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in

the SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect

(“Material Permits”), and neither the Company nor any Subsidiary has received any notice of proceedings relating

to the revocation or modification of any Material Permit.

3.2.9.

Title to Assets. The Company and the Subsidiaries have good and marketable title in fee simple to, or have valid and marketable

rights to lease or otherwise use, all real property and all personal property that is material to the business of the Company and the

Subsidiaries, in each case free and clear of all Liens, except for (i) Liens that do not materially affect the value of such property

and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii)

Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made in accordance with GAAP, and the

payment of which is neither delinquent nor subject to penalties. Neither the Company nor any of its Subsidiaries has received any written

notice of any claim of any sort that has been asserted by anyone adverse to the rights of the Company or its Subsidiaries under any of

the leases or subleases or licenses or with respect to the properties mentioned above, or affecting or questioning the rights of the

Company or any Subsidiary to the continued possession or use of the leased or subleased or licensed premises or the properties mentioned

above, other than such claims which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

3.2.10.

Intellectual Property. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications,

trademarks, trademark applications, service marks, trade names, trade

secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or required for use in

connection with their respective businesses as described in the SEC Reports and which the failure to so have could have a Material Adverse

Effect (collectively, the “Intellectual Property Rights”). None of, and neither the Company nor any Subsidiary

has received notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or

is expected to expire or terminate or be abandoned, within two (2) years after the date of this Agreement. Neither the Company nor any

Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice

of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except

as could not have or reasonably be expected to have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual

Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The

Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their

intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a

Material Adverse Effect.

3.2.11.

Insurance. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such

losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged,

including, but not limited to, directors and officers insurance coverage in amount deemed prudent by the Company. Neither the Company

nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage

expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase

in cost.

3.2.12.

Transactions with Affiliates and Employees. Except as set forth on Schedule 3.2.12, during the past three fiscal years

and the subsequent interim period through the date of this Agreement, none of the officers or directors of the Company or any Subsidiary

and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction

with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement

or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from,

providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director or

such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial

interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i)

payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii)

other employee benefits, including stock option agreements under any stock option plan of the Company.

3.2.13.

Sarbanes-Oxley; Internal Accounting Controls. The Company and the Subsidiaries are in material compliance with any and

all applicable requirements of the Sarbanes-Oxley Act of 2002, as amended, that are effective as of the date hereof, and any and all

applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing

Date. Except as set forth on Schedule 3.2.13, the Company and the Subsidiaries maintain a system of internal accounting controls sufficient

to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific authorizations,

(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset

accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization, and

(iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken

with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in

Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures

to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded,

processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. The Company’s

certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as

of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the “Evaluation

Date”). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the

certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation

Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined

in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect,

the internal control over financial reporting of the Company and its Subsidiaries.

3.2.14.

Certain Fees. Except for the fees and expenses of the Placement Agent, no brokerage or finder’s fees or commissions

are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment

banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no

obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated

in this Section 3.2.14 that may be due in connection with the transactions contemplated by the Transaction Documents.

3.2.15.

Private Placement. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.3,

no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers as contemplated

hereby. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Trading Market.

3.2.16.

Investment Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,

will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended.

The Company shall conduct its business in a manner so that it will not become an “investment company” subject to registration

under the Investment Company Act of 1940, as amended.

3.2.17.

Registration Rights. Except as disclosed on Schedule 3.2.17, no Person has any right to cause the Company or any Subsidiary

to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.

3.2.18.

Listing and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange

Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration

of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating

such registration. The Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which

the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance

requirements of such Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue

to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer

through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to

the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.

3.2.19.

Application of Takeover Protections. The Company and the Board of Directors have taken all necessary action, if any, in

order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights

agreement) or other similar anti-takeover provision under the Company’s certificate of incorporation (or similar charter documents)

or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the

Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result

of the Company’s issuance of the Securities and the Purchasers’ ownership of the Securities.

3.2.20.

Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction

Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their

agents or counsel with any information that it believes constitutes or might constitute material, non-public information. The Company

understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities of the

Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries,

their respective businesses and the transactions contemplated hereby, is true and correct and does not contain any untrue statement of

a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances

under which they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date

of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to

be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made

and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties

with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.3 hereof.

3.2.21.

No Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section

3.3, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any

offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the

Securities to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would require the registration

of any such securities under the Securities Act, or (ii) any applicable stockholder approval provisions of any Trading Market on which

any of the securities of the Company are listed or designated.

3.2.22.

Solvency. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the

receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company’s

assets exceeds the amount that will be required to be paid on or in respect of the Company’s existing debts and other liabilities

(including known contingent liabilities) as they mature, (ii) the Company’s

assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to be conducted including

its capital needs taking into account the particular capital requirements of the business conducted by the Company, consolidated and

projected capital requirements and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds

the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would

be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not

intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable

on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will file

for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year after the Closing Date.

Schedule 3.2.22 sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary,

or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, “Indebtedness”

means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the

ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others,

whether or not the same are or should be reflected in the Company’s consolidated balance sheet (or the notes thereto), except guaranties

by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z)

the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither

the Company nor any Subsidiary is in default with respect to any Indebtedness.

3.2.23.

Tax Status. Except as disclosed in Schedule 3.2.23, the Company and its Subsidiaries each (i) has made or filed all material

United States federal, state and local income and all foreign income

and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all material taxes

and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and

declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent

to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due

by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.

3.2.24.

No General Solicitation. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of

the Securities by any form of general solicitation or general advertising. The Company has offered the Securities for sale only to the

Purchasers and certain other “accredited investors” within the meaning of Rule 501 under the Securities Act.

3.2.25.

Foreign Corrupt Practices Act. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary,

any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful

contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful

payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate

funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf

of which the Company is aware) which is in violation of law or (iv) violated in any material respect any provision of FCPA.

3.2.26.

Accountants. The Company’s accounting firm is Bush & Associates CPA LLC, with offices at 9555 South Eastern Avenue,

Suite 280, Las Vegas, NV 89123. To the knowledge and belief of the Company, such accounting firm (i) is a registered public accounting

firm as required by the Exchange Act and (ii) shall express its opinion with respect to the financial statements to be included in the

Company’s Annual Report for the now current fiscal year.

3.2.27.

No Disagreements with Accountants and Lawyers. There are no disagreements of any kind presently existing, or reasonably

anticipated by the Company to arise, between the Company and the accountants and lawyers formerly or presently employed by the Company

and the Company is current with respect to any fees owed to its accountants and lawyers which could affect the Company’s ability

to perform any of its obligations under any of the Transaction Documents.

3.2.28.

Acknowledgment Regarding Purchasers’ Purchase of Securities. The Company acknowledges and agrees that each of the

Purchasers is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions

contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company

(or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given

by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions

contemplated thereby is merely incidental to the Purchasers’ purchase of the Securities. The Company further represents to each

Purchaser that the Company’s decision to enter into this Agreement and the other Transaction Documents has been based solely on

the independent evaluation of the transactions contemplated hereby by the Company and its representatives.

3.2.29.

Acknowledgment Regarding Purchaser’s Trading Activity. Notwithstanding anything in this Agreement or elsewhere herein

to the contrary (except for Sections 3.3.7 and 4.14 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers

has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities

of the Company, or “derivative” securities based on securities issued by the Company or to hold the Securities for any specified

term, (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales

or “derivative” transactions, before or after the closing of this or future private placement transactions, may negatively

impact the market price of the Company’s publicly-traded securities, (iii) any Purchaser, and counter-parties in “derivative”

transactions to which any such Purchaser is a party, directly or indirectly, presently may have a “short” position in the

Common Stock and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm’s length counter-party

in any “derivative” transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage

in hedging activities at various times during the period that the Securities are outstanding, including, without limitation, during the

periods that the value of the Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging activities

(if any) could reduce the value of the existing stockholders’ equity interests in the Company at and after the time that the hedging

activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any

of the Transaction Documents.

3.2.30.

Regulation M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly

or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company

to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases

of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other

securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company’s placement agent

in connection with the placement of the Securities.

3.2.31.

Officers’ Certificate. Any certificate signed by any duly authorized officer of the Company and delivered to the

Purchasers shall be deemed a representation and warranty by the Company to the Purchasers as to the matters covered thereby.

3.2.32.

D&O Questionnaires. To the Company’s knowledge, all information contained in the questionnaires most recently

completed by each of the Company’s directors and officers and beneficial owner of 5% or more of the shares of Common Stock or Common

Stock Equivalents is true and correct in all respects and the Company has not become aware of any information which would cause the information

disclosed in such questionnaires to become inaccurate and incorrect.

3.2.33.

Stock Option Plans. Each stock option granted by the Company under the Company’s stock option plan, if any, was granted

(i) in accordance with the terms of the Company’s stock option plan and (ii) with an exercise price at least equal to the fair

market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option

granted under the Company’s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has

been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options

with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results

or prospects.

3.2.34.

Office of Foreign Assets Control. Neither the Company nor any Subsidiary nor, to the Company’s knowledge, any director,

officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the

Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”).

3.2.35.

U.S. Real Property Holding Corporation. The Company is not and has never been a U.S. real property holding corporation

within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser’s

request.

3.2.36.

Bank Holding Company Act. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding

Company Act of 1956, as amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve

System (the “Federal Reserve”). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls,

directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent

(25%) or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither

the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or

any entity that is subject to the BHCA and to regulation by the Federal Reserve.

3.2.37.

Money Laundering. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance

with applicable financial record- keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,

as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the “Money

Laundering Laws”), and no Action or Proceeding by or before any court or governmental agency, authority or body or any

arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company

or any Subsidiary, threatened.

3.2.38.

No Disqualification Events. With respect to the Securities to be offered and sold hereunder in reliance on Rule 506 under

the Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer

of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company’s outstanding voting

equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities

Act) connected with the Company in any capacity at the time of sale (each, an “Issuer Covered Person” and,

together, “Issuer Covered Persons”) is subject to any of the “Bad Actor” disqualifications described

in Rule 506(d)(1)(i) to (viii) under the Securities Act (a “Disqualification Event”), except for a Disqualification

Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is

subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e),

and has furnished to the Purchasers a copy of any disclosures provided thereunder.

3.2.39.

Other Covered Persons. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered

Person) that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale

of any Securities.

3.2.40.

Notice of Disqualification Events. The Company will notify the Purchasers and the Placement Agent in writing, prior to

the Closing Date of (i) any Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage

of time, become a Disqualification Event relating to any Issuer Covered Person.

3.2.41.

Cybersecurity. (i) (a) There has been no security breach or other compromise of or relating to any of the Company’s

or any Subsidiary’s information technology and computer systems, networks, hardware, software, data (including the data of its

respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology

(collectively, “IT Systems and Data”) and (b) the Company and the Subsidiaries have not been notified of, and

has no knowledge of any event or condition that would reasonably be expected to result in, any security breach or other compromise to

its IT Systems and Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all

judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual

obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized

use, access, misappropriation or modification, except, in the case of clauses (i) and (ii) herein, as would not, individually or in the

aggregate, have a Material Adverse Effect; (iii) the Company and the Subsidiaries have implemented and maintained commercially reasonable

safeguards to maintain and protect its material confidential information and the integrity, continuous operation, redundancy and security

of all IT Systems and Data; and (iv) the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent

with industry standards and practices.

3.2.42.

Separate and Independent Purchasers. The Company further (a) represents and warrants and acknowledges and agrees that,

to the knowledge of the Company (i) each Purchaser is participating in the offering of Securities contemplated hereby separately and

independently of each other Purchaser, (ii) no Purchaser has communicated directly with any other Purchaser, (iii) all communications

by each Purchaser concerning the Transaction Documents and the transactions contemplated thereby and any matters related thereto were

solely conducted separately and independently with the Placement Agent without the involvement or inclusion of any other Purchaser and

(iv) the Purchasers do not constitute a “group” as that term

is used under Section 13(d) of the Exchange Act.

3.3.

Representations and Warranties of the Purchasers. Each Purchaser, for itself and for no other Purchaser, hereby represents

and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which

case they shall be accurate as of such date):

3.3.1.

Organization; Authority. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing

and in good standing under the law of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited

liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents

and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance

by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate,

partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to

which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof,

will constitute the legal, valid and binding obligation of such Purchaser, enforceable against it in accordance with its terms, except

(i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general

application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific

performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited

by applicable law.

3.3.2.

Own Account. Such Purchaser understands that the Securities are “restricted securities” as defined in Rule

144 and have not been registered under the Securities Act or any applicable state securities law and is acquiring the Securities as principal

for its own account and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities

Act or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities

Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute

or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities law (this representation

and warranty shall not limit such Purchaser’s right to sell the Securities pursuant to a registration statement or otherwise in

compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course

of its business.

3.3.3.

Purchaser Status. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on

each date on which it exercises any Warrants, it will be either: (i) an “accredited investor” as defined in Rule 501(a)(1),

(a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act or (ii) a “qualified institutional buyer”

as defined in Rule 144A(a)(1) under the Securities Act. Such Purchaser hereby represents that neither such Purchaser nor any of its Rule

506(d) Related Parties (as defined below) is a “bad actor” within the meaning of Rule 506(d) promulgated under the Securities

Act. For purposes of this Agreement, “Rule 506(d) Related Party” shall mean a person or entity covered by the “Bad

Actor disqualification” provision of Rule 506(d) of the Securities Act.

3.3.4.

Experience of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication

and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment

in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of

an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.

3.3.5.

General Solicitation. Such Purchaser is not, to such Purchaser’s knowledge, purchasing the Securities as a result

of any advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar

media or broadcast over television or radio or presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation

or general advertisement.

3.3.6.

Access to Information. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents

(including all exhibits and schedules thereto) and the SEC Reports and has been afforded (i) the opportunity to ask such questions as

it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering

of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial

condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment;

and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort

or expense that is necessary to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and

agrees that neither the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or

advice with respect to the Securities nor is such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate

has made or makes any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may

have acquired non-public information with respect to the Company which such Purchaser agrees need not be and has not been provided to

it (other than with respect to the transactions contemplated by the Transaction Documents). In connection with the issuance of the Securities

to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.

3.3.7.

Certain Transactions and Confidentiality. Other than consummating the transactions contemplated hereunder, such Purchaser

has not, nor has any Person acting on behalf of or pursuant to any understanding

with such Purchaser, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company

during the period commencing as of the time that such Purchaser first received a term sheet (written or oral) from the Company or any

other Person representing the Company setting forth the material terms of the transactions contemplated hereunder and ending immediately

prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby

separate portfolio managers manage separate portions of such Purchaser’s assets and the portfolio managers have no direct knowledge

of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s assets, the representation

set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision

to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser’s

representatives, including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates,

such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence

and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute

a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or

similar transactions in the future.

3.3.8.

No Intent to Effect a Change of Control. Such Purchaser has no present intent to effect a “change of control”

of the Company as such term is interpreted and understood under the rules promulgated pursuant to Section 13(d) of the 1934 Act.

The

Company acknowledges and agrees that the representations contained in this Section 3.3 shall not modify, amend or affect such Purchaser’s

right to rely on the Company’s representations and warranties contained in this Agreement or any representations and warranties

contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement

or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained

herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order

to effect Short Sales or similar transactions in the future.

Other Agreements of

the Parties.

4.1.

Transfer Restrictions.

4.1.1.

The Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Securities

other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser or in connection

with a pledge as contemplated in Section 4.1.2, the Company may require the transferor thereof to provide to the Company an opinion of

counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably

satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Securities under the

Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and

shall have the rights and obligations of a Purchaser under this Agreement.

4.1.2.

Each Purchaser agrees to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Securities in substantially

the following form:

NEITHER

THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION

OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED

(THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT

UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS

OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE

OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL

INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY

SUCH SECURITIES.

The

Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered

broker-dealer or grant a security interest in some or all of the Securities to a financial institution that is an “accredited investor”

as defined in Rule 501(a) under the Securities Act and, if required under the terms of such arrangement, such Purchaser may transfer

pledged or secured Securities to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company

and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no

notice shall be required of such pledge. At the appropriate Purchaser’s expense, the Company will execute and deliver such reasonable

documentation as a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities.

4.1.3.

Certificates evidencing the Note Shares and Warrant Shares shall not contain any legend (including the legend set forth in Section 4.1.2

hereof) (i) following any sale of such Note Shares or Warrant Shares pursuant to Rule 144 (assuming cashless exercise of the Warrants),

(ii) if such Note Shares or Warrant Shares are eligible for sale or may be sold under Rule 144 (assuming cashless exercise of the Warrants)

without volume or manner-of-sale restrictions, or (iii) if such legend is not required under applicable

requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission). The

Company shall cause its counsel to issue a legal opinion to the Transfer Agent or the Purchaser if required by the Transfer Agent to

effect the removal of the legend hereunder, or if requested by a Purchaser, respectively. If all or any portion of a Warrant is exercised

at a time when there is an effective registration statement to cover the resale of the Warrant Shares, if the Note Shares or Warrant

Shares may be sold under Rule 144 and the Company is then in compliance with the current public information required under Rule 144 (assuming

cashless exercise of the Warrants), or if the Note Shares or Warrant Shares may be sold under Rule 144 without the requirement for the

Company to be in compliance with the current public information required under Rule 144 as to such Note Shares or Warrant Shares or if

such legend is not otherwise required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements

issued by the staff of the Commission), then such Note Shares or Warrant Shares shall be issued free of all legends. The Company agrees

that following the Resale Effective Date or at such time as such legend is no longer required under this Section 4.1.3, it will, no later

than the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined

below) following the delivery by a Purchaser to the Company or the Transfer Agent of a certificate (or book-entry notation) representing

Note Shares or Warrant Shares, as the case may be, issued with a restrictive legend (such date, the “Legend Removal Date”),

at the Company’s sole cost, deliver or cause to be delivered to such Purchaser a certificate representing such Note Shares or Warrant

Shares, as the case may be, that is free from all restrictive and other legends. The Company may not make any notation on its records

or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section 4. The Company agrees

that no medallion guarantee (or other type of guarantee or notarization) shall be required to remove a legend from any Note Shares or

Warrant Shares, as the case may be. Certificates for Securities subject to legend removal hereunder shall be transmitted by the Transfer

Agent to the Purchaser by crediting the account of the Purchaser’s prime broker with the Depository Trust Company System as directed

by such Purchaser. As used herein, “Standard Settlement Period” means the standard settlement period, expressed in a number

of Trading Days, on the Company’s primary Trading Market with respect to the Common Stock as in effect on the date of delivery

of a certificate (or book-entry notation) representing Note Shares or Warrant Shares, as the case may be, issued with a restrictive legend.

In addition to such Purchaser’s other available remedies, the Company shall pay to the Purchaser, in cash, as partial liquidated

damages and not as a penalty, two percent (2%) of the total of the value of the Note Shares or Warrant Shares for which the removal of

the legend is sought (based on the VWAP of the Common Stock on the date such Note Shares or Warrant Shares are submitted to the Transfer

Agent) for each full month that said opinion is not delivered after the Legend Removal Date until such certificate is delivered without

a legend.

4.1.4.

In addition to such Purchaser’s other available remedies, the Company shall pay to a Purchaser, in cash, (i) as partial liquidated

damages and not as a penalty, for each $1,000 of Note Shares or Warrant

Shares (based on the VWAP of the Common Stock on the date such Securities are submitted to the Transfer Agent) delivered for removal

of the restrictive legend and subject to Section 4.1.3, $10 per Trading Day (increasing to $20 per Trading Day five (5) Trading Days

after the Legend Removal Date) for each Trading Day after the Legend Removal Date until such certificate is delivered without a legend

and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered) to a Purchaser by the Legend Removal Date a certificate

representing the Securities so delivered to the Company by such Purchaser that is free from all restrictive and other legends and (b)

if after the Legend Removal Date such Purchaser purchases (in an open market transaction or otherwise) shares of Common Stock to deliver

in satisfaction of a sale by such Purchaser of all or any portion of the number of shares of Common Stock, or a sale of a number of shares

of Common Stock equal to all or any portion of the number of shares of Common Stock that such Purchaser anticipated receiving from the

Company without any restrictive legend, then, an amount equal to the excess of such Purchaser’s total purchase price (including

brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (including brokerage commissions

and other out-of-pocket expenses, if any) (the “Buy-In Price”) over the product of (A) such number of Note

Shares or Warrant Shares that the Company was required to deliver to such Purchaser by the Legend Removal Date multiplied by (B) the

lowest closing sale price of the Common Stock on any Trading Day during the period commencing on the date of the delivery by such Purchaser

to the Company of the applicable Note Shares or Warrant Shares (as the case may be) and ending on the date of such delivery and payment

under this clause (ii).

4.1.5.

Each Purchaser, severally and not jointly with the other Purchasers, agrees with the Company that such Purchaser will sell any

Securities pursuant to an exemption from the registration requirements of the Securities Act, and acknowledges that the removal of

the restrictive legend from certificates representing Securities as set forth in this Section 4.1 is predicated upon the

Company’s reliance upon this understanding.

4.2.

Furnishing of Information; Public Information.

4.2.1. Until no Purchaser owns any

Securities and the Common Warrants have terminated, the Company covenants to maintain the effectiveness of the registration of the Common

Stock under Section 12(b) or 12(g) of the Exchange Act and to use reasonable best efforts to timely file (or obtain extensions in respect

thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to

the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.

4.2.2.

At any time during the period commencing from the six (6) month anniversary of the date hereof and ending at such time that all of the

Securities (assuming cashless exercise for the Warrants) may be sold without the requirement for the Company to be in compliance with

Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144, if the Company (i) shall fail for any reason to

satisfy the current public information requirement under Rule 144(c) or (ii) has ever been an issuer described in Rule 144(i)(1)(i) or

becomes such an issuer in the future, and the Company shall fail to satisfy any condition set forth in Rule 144(i)(2) (a “Public

Information Failure”) then, in addition to such Purchaser’s other available remedies, the Company shall pay to a

Purchaser, in cash, as partial liquidated damages and not as a penalty, by reason of any such delay in or reduction of its ability to

sell the Securities, an amount in cash equal to two percent (2.0%) of the aggregate Subscription Amount of such Purchaser’s Securities

on the Calendar Day of a Public Information Failure and on every thirtieth

(30th) Calendar Day (prorated for periods totaling less than thirty Calendar Days) thereafter until the earlier of (a) the date such

Public Information Failure is cured and (b) such time that such public information is no longer required for the Purchasers to transfer

the Note Shares and Warrant Shares pursuant to Rule 144. The payments to which a Purchaser shall be entitled pursuant to this Section

4.2.2 are referred to herein as “Public Information Failure Payments.” Public Information Failure Payments

shall be paid on the earlier of (i) the last Calendar Day of the calendar month during which such Public Information Failure Payments

are incurred and (ii) the third (3rd) Business Day after the event or failure giving rise to the Public Information Failure Payments

is cured. If the Company fails to make Public Information Failure Payments in a timely manner, such Public Information Failure Payments

shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in full. Nothing herein shall limit such Purchaser’s

right to pursue actual damages for the Public Information Failure, and such Purchaser shall have the right to pursue all remedies available

to it at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief.

4.3.

Integration. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any

security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner

that would require the registration under the Securities Act of the sale of the Securities or that would be integrated with the offer

or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require stockholder approval

prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction.

4.4.

Securities Laws Disclosure; Publicity. The Company shall (a) by the Disclosure Time, issue a press release disclosing the

material terms of the transactions contemplated hereby, and (b) file, within the time required by the Exchange Act, a Current Report

on Form 8-K, including the Transaction Documents as exhibits thereto, with the Commission. From and after the issuance of such press

release, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered

to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents

(including, without limitation, the Placement Agent). In addition, effective upon the issuance of such press release, the Company acknowledges

and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company,

any of its Subsidiaries, or any of their respective officers, directors, agents (including, without limitation, the Placement Agent),

employees or Affiliates on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate and

be of no further force or effect. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant

in effecting transactions in securities of the Company. The Company and each Purchaser shall consult with each other in issuing any other

press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press

release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any

Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company,

which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing

party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing,

the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission

or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) to the extent required by

federal securities law in connection with the filing of final Transaction Documents with the Commission and (b) to the extent such disclosure

is required by law or Trading Market regulations, in which such cases the Company shall (x) obtain prior advice of competent counsel

that such disclosure is required, (y) provide the Purchasers with prior notice of such disclosure permitted under this Section 4.4 and

(z) reasonably cooperate with such Purchasers regarding such disclosure.

4.5.

Stockholder Rights Plan. No claim will be made or enforced by the Company or, with the consent of the Company, any other

Person, that any Purchaser is an “Acquiring Person” under any control share acquisition, business combination,

poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter

adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of

receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.

4.6.

Non-Public Information. Except with respect to the material terms and conditions of the transactions contemplated by the

Transaction Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other

Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company

reasonably believes constitutes, material non- public information, unless prior thereto such Purchaser shall have consented in writing

to the receipt of such information and agreed in writing with the Company to keep such information confidential. The Company understands

and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To

the extent that the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates

delivers any material, non-public information to a Purchaser without such Purchaser’s consent, the Company hereby covenants and

agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective

officers, directors, agents, employees or Affiliates, or a duty to the Company, any of its Subsidiaries or any of their respective officers,

directors, agents, employees or Affiliates not to trade on the basis of, such material, non-public information, provided that the Purchaser

shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains,

material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously with the delivery of such

notice file such notice with the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that each

Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.

4.7.

Use of Proceeds. The Company shall use the net proceeds from the sale of the Securities hereunder for general corporate

purposes (which for the avoidance of doubt may include acquisitions, in the Company’s discretion), including working capital. The

Company shall not use such proceeds: (a) for the satisfaction of any portion of the Company’s debt (other than payment of trade

payables in the ordinary course of the Company’s business and prior practices), (b) for the redemption of any shares of Common

Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d)

in violation of FCPA or OFAC regulations.

4.8.

Indemnification of each Purchaser. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each

Purchaser and its directors, officers, stockholders, members, partners, employees and agents (and any other Persons with a functionally

equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such

Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, stockholders,

agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding

a lack of such title or any other title) of such controlling persons (each, a “Purchaser Party”) harmless from

any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid

in settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such Purchaser Party may suffer

or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the

Company in this Agreement or in the other Transaction Documents, (b) any action instituted against the Purchaser Parties in any capacity

(including a Purchaser Party’s status as an investor), or any of them or their respective Affiliates, by the Company or any stockholder

of the Company who is not an Affiliate of such Purchaser Party, arising out of or relating to any of the transactions contemplated by

the Transaction Documents. For the avoidance of doubt, the indemnification provided herein is intended to, and shall also cover, direct

claims brought by the Company against the Purchaser Parties; provided, however, that such indemnification shall not cover any loss, claim,

damage or liability to the extent it is finally judicially determined to be attributable to such Purchaser Party’s material breach

of any of the representations, warranties or covenants made by such Purchaser Party in any Transaction Document or any conduct by such

Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct). If any action shall

be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall

promptly notify the Company in writing, and, except with respect to direct claims brought by the Company, the Company shall have the

right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party

shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses

of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically

authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ

counsel or (iii) in such action there is, in the reasonable opinion of counsel to the applicable Purchaser Party (which may be internal

counsel), a material conflict on any material issue between the position of the Company and the position of such

Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate

counsel. The Company will not be liable to any Purchaser Party under this Agreement for any settlement by a Purchaser Party effected

without the Company’s prior written consent, which shall not be unreasonably withheld or delayed. In addition, if any Purchaser

Party takes actions to collect amounts due under any Transaction Documents or to enforce the provisions of any Transaction Documents,

then the Company shall pay the costs incurred by such Purchaser Party for such collection, enforcement or action, including, but not

limited to, attorneys’ fees and disbursements. The indemnification and other payment obligations required by this Section 4.8 shall

be made by periodic payments of the amount thereof during the course of the investigation, defense, collection, enforcement or action,

as and when bills are received or are incurred; provided, however, that if any Purchaser Party is finally judicially determined not to

be entitled to indemnification or payment under this Section 4.8, such Purchaser Party shall promptly reimburse the Company for any payments

that are advanced under this sentence. The indemnity agreements contained herein shall be in addition to any cause of action or similar

right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law.

4.9.

Listing of Common Stock. The Company hereby agrees to use its best efforts to maintain the listing or quotation of the

Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list

or quote all of the Note Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Note Shares and

Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other

Trading Market, it will then include in such application all of the Note Shares and Warrant Shares, and will take such other action as

is necessary to cause all of the Note Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible.

The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market

and will comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of the Trading

Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company

or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company

or such other established clearing corporation in connection with such electronic transfer.

4.10.

Stockholder Approval. The Company shall hold a special meeting of stockholders (which may also be at the annual meeting

of stockholders) at the earliest practicable date after the date hereof, but in no event later than sixty (60) Calendar Days after the

Closing Date for the purpose of obtaining Stockholder Approval (such meeting, the “Stockholder Approval Meeting”),

with the recommendation of the Company’s Board of Directors that such proposal be approved, and the Company shall solicit proxies

from its stockholders in connection therewith in the same manner as all other management proposals in such proxy statement and all management-appointed

proxyholders shall vote their proxies in favor of such proposal. The Company shall use its reasonable best efforts to obtain such Stockholder

Approval. The Stockholder Approval Meeting shall not be held between 9:30 a.m.

(New York City time) and 4:02 p.m. (New York City time) on any Trading Day, and the Company shall file a Current Report on Form 8-K announcing

the voting results of the Stockholder Approval Meeting prior to 9:00 a.m. (New York City time) on the Trading Day immediately following

the Stockholder Approval Meeting (i.e., the same Trading Day if the Stockholder Approval Meeting is held prior to 9:30 a.m. (New York

City time) on a Trading Day). If the Company does not obtain Stockholder Approval at the first meeting, the Company shall call a meeting

every sixty (60) days thereafter to seek Stockholder Approval until the earlier of the date Stockholder Approval is obtained or the Common

Warrants are no longer outstanding. Notwithstanding the foregoing, the Company may, in lieu of holding a special meeting of stockholders

as aforesaid, obtain the written consent of a majority of its stockholders covering the Stockholder Approval so long as prior to sixty

(60) Calendar Days after the date hereof, such written consents are obtained and in accordance with Exchange Act Rule 14c-2 at least

twenty (20) Calendar Days shall have transpired after the date on which a written information statement containing the information specified

in Schedule 14C detailing such Stockholder Approval shall have been filed with the SEC and delivered to stockholders of the Company.

4.11.

Equal Treatment of Purchasers. No consideration (including any modification of any Transaction Document) shall be offered

or paid to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration

is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate

right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat

the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the

purchase, disposition or voting of Securities or otherwise.

4.12.

Certain Transactions and Confidentiality. Each Purchaser, severally and not jointly with the other Purchasers, covenants

that neither it, nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales,

including Short Sales, of any of the Company’s securities during the period commencing with the execution of this Agreement and

ending at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release

as described in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the

transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described

in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction. Notwithstanding the

foregoing and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that

(i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities

of the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial

press release as described in Section 4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any

securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated by

this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser

shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company, any of

its Subsidiaries, or any of their respective officers, directors, employees, agents or Affiliates after the issuance of the initial press

release as described in Section 4.4. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle

whereby separate portfolio managers manage separate portions of such Purchaser’s assets and the portfolio managers have no direct

knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s assets, the covenant

set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision

to purchase the Securities covered by this Agreement.

4.13.

Form D; Blue Sky Filings. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation

D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall reasonably

determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to the Purchasers at the Closing under

applicable securities or “Blue Sky” laws of the states of the United States, and shall provide evidence of such actions promptly

upon request of any Purchaser.

4.14.

Acknowledgment of Dilution. The Company acknowledges that the issuance of the Securities may result in dilution of the

outstanding shares of Common Stock, which dilution may be substantial under certain market conditions. The Company further acknowledges

that its obligations under the Transaction Documents, including, without limitation, its obligation to issue the Note Shares and Warrant

Shares pursuant to the Transaction Documents, are unconditional and absolute and not subject to any right of set off, counterclaim, delay

or reduction, regardless of the effect of any such dilution or any claim the Company may have against any Purchaser and regardless of

the dilutive effect that such issuance may have on the ownership of the other stockholders of the Company.

4.15.

Lock-Up Agreements. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements

(and any lock-up agreements contemplated in the Lock-Up Agreements) except to extend the term of the lock-up period and shall enforce

the provisions of each Lock-Up Agreement (and any lock-up agreements contemplated in the Lock-Up Agreements) in accordance with its terms.

If any party to a Lock-Up Agreement (and any lock-up agreements contemplated in the Lock-Up Agreements) breaches any provision of a Lock-Up

Agreement, the Company shall promptly use its best efforts to seek specific performance of the terms of such Lock-Up Agreement (and any

lock-up agreements contemplated in the Lock-Up Agreements).

4.16.

Reservation of Common Stock. As of the date hereof, the Company has reserved and the Company shall continue to reserve

and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling

the Company to issue the maximum number of Note Shares issuable upon conversion of the Note and the maximum number of Warrant Shares

issuable upon exercise of the Warrants (calculated assuming (i) conversion in full of all outstanding principal of, and all accrued and

unpaid interest on, the Note at the Conversion Price (as defined in the Note) and (ii) exercise in full of all of the Warrants at the

Exercise Price (as defined in the Warrants), and in any event equal to not less than 300% of such number) (as adjusted for forward

and reverse stock splits, recapitalizations, stock dividends and the like after the date hereof). If the Company does not have a sufficient

number of shares of Common Stock available to honor the conversion of the Note or the exercise of the Warrants, the Company shall allocate

the available number of Note Shares and Warrant Shares on a pro rata basis among all Purchasers converting the Note or exercising Warrants,

until such time as the Company has a sufficient number of authorized shares of Common Stock to issue all Note Shares and Warrant Shares

in full.

4.17.

Conversion Procedures. The form of Notice of Conversion included in the Note sets forth the totality of the procedures

required of the Purchasers in order to convert the Note. No additional legal opinion, other information or instructions shall be required

of the Purchasers to convert the Note, and, without limiting the preceding sentence, no ink- original Notice of Conversion shall be required,

nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Conversion form be required in order

to convert the Note. The Company shall honor conversions of the Note and shall deliver Note Shares in accordance with the terms, conditions

and time periods set forth in the Transaction Documents.

4.18.

Exercise Procedures. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required

of the Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required

of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required,

nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to

exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms,

conditions and time periods set forth in the Transaction Documents.

Miscellaneous.

5.1.

Termination. This Agreement may be terminated by any Purchaser, as to such Purchaser’s obligations hereunder only

and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties,

if the Closing has not been consummated on or before the fifth (5th) Trading Day following the date hereof; provided, however,

that no such termination will affect the right of any party to sue for any breach by any other party (or parties).

5.2.

Fees and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the

fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident

to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees

(including, without limitation, any fees required for same-Calendar Day processing of any instruction letter delivered by the Company

and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any

Securities to the Purchasers.

5.3.

Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding

of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written,

with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.

5.4.

Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall

be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication

is delivered via email at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City

time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via email

at the email address as set forth on the signature pages attached hereto on a Calendar Day that is not a Trading Day or later than 5:30

p.m. (New York City time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent by U.S.

nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given.

The address for such notices and communications shall be as set forth on the signature pages attached hereto. To the extent that any

notice provided pursuant to any Transaction Document constitutes, or contains material, non-public information regarding the Company

or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form

8-K.

5.5.

Amendments; Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a written

instrument signed, in the case of an amendment, by the Company and Purchasers which hold a majority in interest of the aggregate outstanding

principal amount of the Note based on the initial Subscription Amounts hereunder (or, prior to Closing, the Company and each Purchaser)

or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment,

modification or waiver disproportionately and adversely impacts a Purchaser (or multiple Purchasers), the consent of such disproportionately

impacted Purchaser (or multiple Purchasers) shall also be required. No waiver of any default with respect to any provision, condition

or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver

of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder

in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely

affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require

the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding

upon each Purchaser and holder of Securities and the Company.

5.6.

Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed

to limit or affect any of the provisions hereof.

5.7.

Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors

and permitted assigns. The Company may not assign this Agreement or any

rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). Any Purchaser may assign

any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided that

such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction Documents

that apply to the “Purchasers.”

5.8.

No Third-Party Beneficiaries. The Placement Agent shall be the third party beneficiary of the representations and warranties

of the Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.3. This Agreement is intended for

the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision

hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.

5.9.

Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents

shall be governed by and construed and enforced in accordance with the law of the State of New York without regard to the principles

of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of

the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective

affiliates, directors, officers, stockholders, partners, members, employees or agents) shall be commenced exclusively in the state and

federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and

federal courts sitting in the City and County of New York for the adjudication of any dispute hereunder or in connection herewith or

with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents),

and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the

jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party

hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing

a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect

for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice

thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the

obligations of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing

party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution

of such Action or Proceeding.

5.10.

Survival. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.

5.11.

Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered

one and the same agreement and shall become effective when counterparts

have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart.

If any signature is delivered by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding

obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such “.pdf”

signature page were an original thereof.

5.12.

Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction

to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall

remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially

reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated

by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would

have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared

invalid, illegal, void or unenforceable.

5.13.

Rescission and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar

provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction

Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may

rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election

in whole or in part without prejudice to its future actions and rights; provided, however, that, in the case of a rescission

of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded

exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and

the restoration of such Purchaser’s right to acquire such shares pursuant to such Purchaser’s Warrant (including, issuance

of a replacement warrant certificate evidencing such restored right).

5.14.

Replacement of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed,

the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),

or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to

the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also

pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.

5.15.

Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of

damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties

agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in

the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation

the defense that a remedy at law would be adequate. All rights and remedies of the Purchasers under the Transaction Documents, at law

and in equity, are cumulative and not alternative, and the exercise of any one right or remedy shall not preclude the exercise of any

other. Without limiting the foregoing, the failure of the Company to pay any Principal, Interest or other amount when due under the Note

or any other Transaction Document shall constitute an immediate Event of Default under the Note, without any requirement of notice, demand

or cure period, and each Purchaser shall be entitled to exercise all rights and remedies available to it under the Note, the other Transaction

Documents and applicable law, including the right to accelerate all amounts owing thereunder and to recover all costs of collection and

enforcement (including reasonable attorneys’ fees).

5.16.

Payment Set Aside. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction

Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement

or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged

by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law

(including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent

of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force

and effect as if such payment had not been made or such enforcement or setoff had not occurred.

5.17.

Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction

Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for

the performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein

or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute

the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers

are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents.

Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out

of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an

additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review

and negotiation of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel

have chosen to communicate with the Company through the legal counsel to the Placement Agent. The legal counsel of the Placement Agent

does not represent any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers with

the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by

any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction

Document is between the Company and a Purchaser, solely, and not between

the Company and the Purchasers collectively and not between and among the Purchasers.

5.18.

Liquidated Damages. The Company’s obligations to pay any partial liquidated damages or other amounts owing under

the Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages

and other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages

or other amounts are due and payable shall have been canceled.

5.19.

Saturdays, Sundays, Holidays, etc. If the last or appointed Calendar Day for the taking of any action or the expiration

of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on

the next succeeding Business Day.

5.20.

Construction. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity

to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved

against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition,

each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse

and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the

date of this Agreement.

5.21.

WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE

PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY

AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.

[PARA

Securities Purchase Agreement Signature Pages Follow]

[PARA

Securities Purchase Agreement – Company Signature Page]

WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized

signatories as of the date first indicated above.

BANZAI INTERNATIONAL, INC.

Address for Notice:

By:

Email:

Name:

Joseph Davy

Title:

Chief Executive Officer

[PARA

Securities Purchase Agreement – Investor Signature Page]

WITNESS WHEREOF, the undersigned has caused this Securities Purchase Agreement to be duly executed by its authorized signatory as of

the date first indicated above.

Name of Purchaser:

[●]

Signature of Authorized Signatory of Purchaser:

Name of Authorized Signatory:

[●]

Title of Authorized Signatory:

[●]

Email Address of Authorized Signatory:

[●]

Address for Notice to Purchaser:

[●]

Address for Delivery of Securities to Purchaser (if not same as address

for notice):

[●]

Subscription Amount:

[●]

1,500,000

Note (Initial Principal Amount):

[●]

2,142,857.14

Common Warrants:

[●]

779,221

Beneficial Ownership Blocker:

[●]

4.99%

Employer Identification Number:

[●]

Exhibit

1.16.1

Form

of PIPE Common Warrant

Exhibit

1.34

Form

of Lock-Up Agreement

Exhibit

1.38

Form

of Convertible Promissory Note

EX-10.2

Filename: ex10-2.htm · Sequence: 5

Exhibit

10.2

BANZAI

INTERNATIONAL, INC. - LOCK-UP AGREEMENT

September

4, 2026

Banzai

International, Inc.

435

Ericksen Ave NE

Suite

250

Bainbridge

Island, WA 98110

United

States

Ladies

and Gentlemen:

The

undersigned understands that Banzai International, Inc., a Delaware corporation (the “Company”), entered into

a Securities Purchase Agreement (the “SPA”) on September 4, 2026 with each purchaser (each, a “Purchaser”,

and collectively “Purchasers”) identified on the signature page of the SPA, providing for the private placement

(the “Transaction”) of unsecured convertible promissory notes (the “Notes”), convertible

into Class A ordinary shares of Common Stock, $0.0001 par value per share, of the Company (“Shares”) and warrants

(“Warrants”) to purchase shares of Common Stock. Capitalized terms used but not defined in this Agreement have

the meanings ascribed to them in the SPA.

induce the Company to continue its efforts in connection with the Transaction, the undersigned hereby irrevocably enters into this Lock-Up

Agreement (this “Agreement”) and agrees that the undersigned will not, during the period commencing on the

date hereof and ending on the date that is ninety (90) calendar days thereafter (the “Lock-Up Period”), (1)

offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, any Shares or any securities

convertible into or exercisable or exchangeable for Shares, whether now owned or hereafter acquired by the undersigned (or any Affiliate

(as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned) or with respect to which the undersigned

(or any Affiliate of the undersigned) has or hereafter acquires the power of disposition (collectively, the “Lock-Up Securities”);

(2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership

of the Lock-Up Securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Lock-Up

Securities, in cash or otherwise; (3) make any demand for or exercise any right with respect to the registration of any Lock-Up Securities;

or (4) publicly disclose the intention to make any offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge

or other arrangement relating to any Lock-Up Securities.

Notwithstanding

the foregoing, and subject to the conditions below, the undersigned may transfer Lock-Up Securities in connection with any of the following:

transfers of Lock-Up Securities

as a bona fide gift, by will or intestacy or to a family member or trust for the benefit of the undersigned (for purposes of

this Agreement, “family member” means any relationship by blood, marriage or adoption, not more remote than first cousin)

provided that the transferee agrees to sign and deliver a lock-up agreement substantially in the form of this Agreement for

the balance of the Lock-Up Period.

transfers of Lock-Up Securities

to a charity or educational institution.

if the undersigned is a corporation,

partnership, limited liability company or other business entity, (i) any transfers of Lock-Up Securities to another corporation, partnership

or other business entity that controls, is controlled by or is under common control with the undersigned or (ii) distributions of Lock-Up

Securities to members, partners, stockholders, subsidiaries or Affiliates of the undersigned as of the date of this Agreement, provided

that the transferee agrees to sign and deliver a lock-up agreement substantially in the form of this Agreement for the balance of the

Lock-Up Period.

if the undersigned is a trust,

to a trustee or beneficiary of the trust provided that in the case of any transfer pursuant to Sections 1, 2, 3 or this section:

4.1.

any such transfer shall not involve a disposition for value,

4.2.

each transferee shall sign and deliver to the Company a lock-up agreement substantially in the form of this Agreement and

4.3.

no filing under Section 13 or Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)

or other public announcement shall be required or shall be voluntarily made during the Lock-Up Period.

the receipt by the undersigned

from the Company of Shares upon the vesting of restricted stock awards or stock units or upon the exercise of options to purchase the

Shares issued under an equity incentive plan of the Company or an employment arrangement (the “Plan Shares”)

or the transfer or withholding of Shares or any securities convertible into Shares to the Company upon a vesting event of the Company’s

securities or upon the exercise of options to purchase the Company’s securities, in each case on a “cashless” or

“net exercise” basis or to cover tax obligations of the undersigned in connection with such vesting or exercise provided

that if the undersigned is required to file a report under Section 13 or Section 16 of the Exchange Act reporting a reduction in beneficial

ownership of Shares during the Lock-Up Period, the undersigned shall include a statement in such schedule or report to the effect that

the purpose of such transfer was to cover tax withholding obligations of the undersigned in connection with such vesting or exercise

and, provided further that the Plan Shares shall be subject to the terms of this Agreement.

the establishment of a trading

plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of Lock-Up Securities provided that (i) such plan does

not provide for the transfer of Lock-Up Securities during the Lock-Up Period and (ii) no filing under Section 13 or Section 16 of the

Exchange Act or any other public announcement shall be required or voluntarily made during the Lock-Up Period.

the transfer of Lock-Up Securities

that occurs by operation of law, such as pursuant to a qualified domestic order or in connection with a divorce settlement, provided

that the transferee agrees to sign and deliver a lock-up agreement substantially in the form of this Agreement for the balance of the

Lock-Up Period, and provided further that any filing under Section 13 or Section 16 of the Exchange Act that is required to

be made during the Lock-Up Period as a result of such transfer shall include a statement that such transfer has occurred by operation

of law; and provided further that competent legal counsel for the Company shall have first advised that such transfer is a mandatory

and not voluntary transfer.

the transfer of Lock-Up Securities

pursuant to a bona fide third party tender offer, merger, consolidation or other similar transaction made to all holders of the Shares

involving a change of control (as defined below) of the Company after the closing of the Transaction and approved by the Company’s

board of directors; provided that in the event that the tender offer, merger, consolidation or other such transaction is not

completed, the Lock- Up Securities owned by the undersigned shall remain subject to the restrictions contained in this Agreement. A

“change of control” shall mean the consummation of any bona fide third party tender offer, merger, amalgamation, consolidation

or other similar transaction the result of which is that any “person” (as defined in Section 13(d)(3) of the Exchange Act),

or group of persons, becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 of the Exchange Act) of a majority of total

voting power of the voting stock of the Company.

The

undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar

against the transfer of the undersigned’s Lock-Up Securities except in compliance with this Agreement.

This

Agreement may not be amended or otherwise modified in any respect without the written consent of each of the Company and the undersigned.

This Agreement shall be governed by and construed in accordance with the law of the State of New York. The undersigned hereby irrevocably

submits to the exclusive jurisdiction of the United States District Court sitting in the Southern District of New York and the courts

of the State of New York located in the City and County of New York, for the purposes of any suit, action or proceeding arising out of

or relating to this Agreement, and hereby waives, and agrees not to assert in any such suit, action or proceeding, any claim that (i)

it is not personally subject to the jurisdiction of such court, (ii) the suit, action or proceeding is brought in an inconvenient forum,

or (iii) the venue of the suit, action or proceeding is improper. The undersigned hereby irrevocably waives personal service of process

and consents to process being served in any such suit, action or proceeding by receiving a copy thereof sent to the Company at the address

in effect for notices to it under the SPA and agrees that such service shall constitute good and sufficient service of process and notice

thereof. The undersigned hereby waives any right to a trial by jury. Nothing contained herein shall be deemed to limit in any way any

right to serve process in any manner permitted by law. The undersigned agrees and understands that this Agreement does not intend to

create any relationship between the undersigned and any Purchaser and that no Purchaser is entitled to cast any votes on the matters

herein contemplated and that no issuance or sale of the Securities is created or intended by virtue of this Agreement.

The

undersigned understands that the Company is relying upon this Agreement in proceeding toward consummation of the Transaction. The undersigned

further understands that this Agreement is irrevocable and shall be binding upon the undersigned’s heirs, legal representative,

successors and assigns. This Letter Agreement is intended for the benefit of the parties hereto and their respective successors and permitted

assigns and is not for the benefit of, nor may any provisions hereof be enforced by, any other person or entity.

The

undersigned understands that, if the SPA is not executed by September 4, 2026 or if the SPA (other than the provisions thereof which survive

termination) shall terminate or be terminated prior to payment for and delivery of the Shares to be sold thereunder, then this Agreement

shall be void and of no further force or effect.

Whether

or not the Transaction actually occurs depends on a number of factors, including market conditions. Any Transaction will only be made

pursuant to the SPA.

[PARA

Lock-Up Agreement Signature Page Follows]

[PARA

Lock-Up Agreement Signature Page]

The

undersigned has read and agrees to be bound by the terms of this Agreement dated as of September 4, 2026.

Very

truly yours,

(Signature)

Name:

Address:

Email:

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 22

v3.26.1

Cover

Sep. 11, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 11, 2026

Entity File Number

001-39826

Entity Registrant Name

Banzai

International, Inc.

Entity Central Index Key

0001826011

Entity Tax Identification Number

85-3118980

Entity Incorporation, State or Country Code

Entity Address, Address Line One

435

Ericksen Ave

Entity Address, Address Line Two

Suite 250

Entity Address, City or Town

Bainbridge

Island

Entity Address, State or Province

Entity Address, Postal Zip Code

98110

City Area Code

(206)

Local Phone Number

414-1777

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Class A common stock, par value $0.0001 per share

Title of 12(b) Security

Class

A common stock, par value $0.0001 per share

Trading Symbol

PARA

Security Exchange Name

NASDAQ

Redeemable Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $115,000.00

Title of 12(b) Security

Redeemable

Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $115,000.00

Trading Symbol

PARAW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=BNZI_ClassCommonStockParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=BNZI_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceOf115000.00Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type: